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FiO2 fraction of inspired oxygen
FVC forced vital capacity
HLA human leukocyte antigen
HPV hypoxic pulmonary vasoconstriction
HR heart rate
IASP International Association for the Study of Pain
i.m. intramuscular(ly)
i.v. intravenous(ly)
i.t. intrathecal(ly)
IVY bleeding time using the method published by Ivy (1941)
K/R+K coagulation time
MA maximum amplitude
Mo morphine
NaCl sodium chloride
NMDA N-methyl-D-aspartate
NSAID nonsteroidal anti-inflammatory drug
PaCO2 carbon dioxide tension in arterial blood
PACU postoperative anaesthesia care unit
PaO2 oxygen tension in arterial blood
PCA patient controlled analgesia
PCEA patient controlled epidural analgesia
PTPS postthoracotomy pain syndrome
R reaction time
RR respiratory rate
s.c. subcutaneous
SEM standard error of mean
SpO2 pulse oximetry
TEG thromboelastography
TENS transcutaneous electrical nerve stimulation
VAS visual analogue scale
VAS% percentage of the maximum value on a visual analogue scale
VASpi visual analogue scale pain intensity
VATS video-assisted thoracic surgery
VRS verbal rating scale
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3 ABSTRACT
Pain treatment after thoracic operations
is particularly important because the post-
operative recovery of patients undergoing
thoracic surgery is dependent on the main-
tenance of respiratory function. Respiratory
depression is one of the disadvantages of
opioids commonly used for postoperative
pain treatment. On the other hand, there
are several regional analgesic methods,
which can be used for pain treatment after
thoracic surgery without the adverse events
associated with opioids. These techniques
include intercostal, intrapleural, intraspinal
and paravertebral blockade. Nonsteroidal
anti-inflammatory drugs (NSAIDs) have be-
come popular in combination with opioids
for treatment of postoperative pain, al-
though no reliable data exist on the intra-
venous dosage of NSAIDs.
The objective of the present series of
studies was to compare the efficacy and ad-
verse events of intravenous morphine,
NSAIDs and three different local analgesic
methods in pain relief after two types of
thoracic surgery, and to compare the effi-
cacy and adverse events of intravenous and
i.t. morphine in pain relief after transsternal
thymectomy in myasthenia gravis patients,
who are especially in danger of postopera-
tive respiratory depression. This series of
studies was also intended to investigate the
incidence, duration and severity of persis-
tent postthoracotomy pain, and to assess
the associated risk factors.
Altogether 442 patients were included
in these six different studies. Study I with
207 thoracotomy patients was a retrospec-
tive study whereas study VI with 110 thora-
cotomy patients was a prospective follow-
up study. Studies II and IV were randomised,
placebo-controlled studies with 30 patients
in each undergoing thoracic surgery and
studies III and V were open, randomised
studies with altogether 65 patients under-
going thoracic surgery.
All patients in the consecutive studies II
– V were allowed to take supplementary
doses of morphine intravenously from a
patient-controlled analgesia (PCA) device
during the first two postoperative days. Vi-
sual analogue scale (VAS) (studies II – V),
four-point verbal rating scale (VRS) (studies
II – IV), five-point verbal rating scale (study
VI) and the McGill pain questionnaire (study
VI) were used for pain measurement. Arte-
rial blood gas analysis was performed in
studies II – V up to the second postopera-
tive day. Special attention was paid to uri-
nary output in studies II and IV. Haemato-
logical effects were measured in studies II
and IV using the IVY bleeding time, the
platelet adhesion test (Adeplat S®) and
thromboelastography. Drug concentrations
were measured in studies III – V. In studies II
– V the patients were evaluated for adverse
events and were asked to rate their perfor-
mance status. Patients in the questionnaire
studies (studies I and VI) were interviewed
using standardised questions.
The incidence of chronic postthoraco-
tomy pain was 80% at 3 months, 75% at 6
months and 61% one year after surgery
(study VI). The incidence of severe pain was
3 – 5%. Chronic postthoracotomy pain in-
terfered with normal daily life in more than
half of the patients. In study I cumulative
opioid consumption during the first 24
hours was 57 – 61% lower than in thorac-
otomy studies II – III whereas in study VI
cumulative opioid consumption was only 9
– 18% lower. On the basis of the visual ana-
logue scale pain intensity at rest (VASpi) con-
trol patients experienced more pain after
thoracotomy compared with thoracoscopy
(48% vs. 34% of the maximum value). The
mean cumulative morphine consumption in
the control patients in thoracotomy studies
II – III after the first 24 hours was 72.5 –
80.4 mg whereas in the thoracoscopy study
(IV) it was 66.6 mg and in the sternotomy
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study (V) it was 50.4 mg. In study II, the
consumption of morphine was 60% lower
than in the control group on the first post-
operative day and 76% lower on the sec-
ond postoperative day. In study IV, the mean
consumption of morphine in the control
group was 57 mg; both diclofenac and
ketorolac were equally effective in reducing
total morphine consumption (61% and
52%, respectively). In study III, all three lo-
cal anaesthetic methods, intrapleural, epi-
dural and paravertebral, provided equally
effective pain relief after thoracic surgery.
In study III moderate to severe respiratory
depression was detected in 14 of 45 patients
more than 2 hours after surgery. In thymec-
tomy patients (study V), FVC recovered to
60% of baseline and FEV1 to 57% in the i.t.
morphine group compared with 32% and
37% in the PCA morphine group.
It is concluded that postthoracotomy
pain is usually severe and may require high
doses of opioids. Intravenously administered
NSAIDs improved analgesia and significantly
reduced morphine consumption. NSAIDs
were safe with regard to both haemostasis
and renal function. None of the three local
anaesthetic techniques with comparable
risk-benefit ratios used in the studies, i.e.
intercostal, epidural and paravertebral block-
ade, produced good pain relief after thora-
cotomy. The required PCA-doses of mor-
phine were high and respiratory depression
occurred in one third of the patients. In
myasthenia gravis patients i.t. morphine
provided effective poststernotomy pain re-
lief and significantly improved ventilatory
function when compared with PCA mor-
phine. The high incidence of postpuncture
headache was a serious disadvantage. In
myasthenia gravis patients careful postop-
erative monitoring is required because of the
relatively compromised muscle strength in
these patients and the attendant possibility
of respiratory depression due to pain
therapy. Chronic postthoracotomy pain is a
serious problem following surgery for be-
nign and malignant disease alike.
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4 INTRODUCTION
It is a well-known fact that many pa-
tients experience moderate to severe pain
after surgery due to inadequate pain treat-
ment and every effort should be made to
overcome this phenomenon. One of the
most severe types of postoperative pain has
been reported after thoracic surgery. Some
patients develop chronic postthoracotomy
pain that may last for months or years. In
addition, severe postoperative pain contrib-
utes to postoperative pulmonary dysfunc-
tion. The choice of perioperative analgesic
technique may play an important role here.
The sources of pain are multiple, i.e. the site
of the surgical incision, damage to ribs and
intercostal nerves, inflammation of chest
wall structures, incision or crushing of pul-
monary parenchyma or pleura, and the
placement of thoracotomy drainage tubes.
Systemic opioids have been used tradition-
ally for the treatment of postthoracotomy
pain, but in recent years new methods and
techniques, i.e. nonsteroidal anti-inflamma-
tory drugs, epidural or intrathecal opioids
and different regional analgesic techniques,
have become more popular. However, some
of these new delivery systems and tech-
niques are potentially hazardous.
Numerous studies are available concern-
ing pain treatment after thoracic surgery, but
there still is no effective pain treatment,
which carries a minimum of risk, is cost ef-
fective and is easy to put in to practice. The
present series of studies was carried out to
assess the effectiveness of intravenous and
intrathecal morphine, nonsteroidal anti-in-
flammatory drugs and three different re-
gional analgesic techniques after three types
of thoracic surgery. Two of the studies in-
vestigated the incidence, duration, severity
and risk factors of persistent postthorac-
otomy pain.
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5 REVIEW OF LITERATURE
5.1 Pain after thoracic surgery
5.1.1 Definition of pain
Pain is defined as ‘an unpleasant sen-
sory and emotional experience associated
with actual or potential tissue damage, or
described in terms of such damage’ (Inter-
national Association for the Study of Pain,
Subcommittee of Taxonomy 1986b). Acute
pain is a physiologic reaction to acute
trauma or tissue damage. Pain is chronic if
it recurs or persists (e.g. along a thoracotomy
scar) at least two months following the sur-
gical procedure (International Association
for the Study of Pain, Subcommittee of Tax-
onomy 1986a). Pain is always subjective and
unpleasant and therefore also an emotional
experience (International Association for the
Study of Pain, Subcommittee of Taxonomy
1986b).
5.1.2 Neurophysiology of pain
5.1.2.1 Peripheral tissues
Peripheral pain receptors (nociceptors)
can be identified in all tissues. Pain is usu-
ally initiated by excitation of nociceptors or
afferent nerve fibres. These fibres belong to
the A-δ and C classes. The small-diameter
myelinated A-δ fibres are associated with
sharp, well-localised pain and unmyelinated
C fibres with dull, burning diffusely localised
pain. The C-fibre conduction rate is much
slower than that of the A-δ fibres. C-fibre
activity predominates in continuing pain.
The C fibres also include efferent sympa-
thetic fibres, which probably increase the
sensitivity of peripheral nociceptors to pain.
These primary afferent nerve fibres, i.e. A-δ
and C fibres, project to the dorsal horn of
the spinal cord. They represent the first site
in the pain pathway where pain conduction
can be modulated (Phillips and Cousins
1986).
Responsiveness of peripheral pain re-
ceptors can be increased by factors which
include physical stimuli, the chemical envi-
ronment, endogenous algesic substances as
prostaglandins, serotonin and bradykinin,
changes in the microcirculatory blood sup-
ply, and increased efferent sympathetic ac-
tivity (Phillips and Cousins 1986).
Nociceptive visceral afferents are sym-
pathetic fibres, which pass via cervicotho-
racic sympathetic ganglia from thoracic vis-
cera to the dorsal horn neurons in the spi-
nal cord. Here visceral afferents converge
on the same dorsal horn neurons as somatic
nociceptive afferents. Peripheral visceral af-
ferents branch considerably, causing much
overlap in the territory of individual dorsal
roots. Visceral afferents converge on the
dorsal horn over a large number of seg-
ments. Therefore, visceral pain is poorly
localised and vague, may be cramping and
aching and may be referred to another area
(Phillips and Cousins 1986).
5.1.2.2 Spinal cord
Cell bodies of primary afferent fibres are
contained in dorsal root ganglia and trigemi-
nal sensory ganglia. Primary afferent trans-
mission usually begins in the peripheral pro-
cesses and travels centrally past dorsal root
ganglion cells to the dorsal roots. Large fi-
bres from the dorsal root enter the dorsal
columns, but collaterals also go to the dor-
sal horn (Phillips and Cousins 1986). Fine
fibres enter a longitudinal tract before en-
tering the dorsal horn areas. In the ventral
roots 15 to 30 percent of axons are sensory
(Coggeshall et al. 1975). The synapse be-
tween the small diameter afferent fibres and
the dorsal horn neuron of the spinal cord
represents the second site in the pain path-
way where pain conduction can be modu-
lated.
Certain cells in the dorsal horn of the
spinal cord respond preferentially or exclu-
sively to nociceptive input. Substance P, an
undecapeptide, is present in the terminals
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of nociceptive neurons in the dorsal horn.
Peripherally stimulated A-δ  fibres induce the
release of substance P in the spinal cord
(Cousins and Bridenbaugh 1998). Adminis-
tering opioids before stimulating nerve fi-
bres decreases substance P release, which
would appear to indicate a presynaptic ef-
fect of opioids on various nociceptive fibres
(Jessel and Iversen 1977). Other peptides
that may play a role in primary afferent trans-
mission include neurotensin, vasoactive in-
testinal peptide, and cholecystokinin. Inhi-
bition of transmission by descending path-
ways probably involves noradrenergic, se-
rotonergic, enkephalinergic, and gamma-
aminobutyric acid (GABA) systems (Yaksh
and Chaplan 1997, Cousins and Briden-
baugh 1998).
5.1.2.3 Brain
Nociceptive information is transmitted
to different regions of the brain by ascend-
ing tracts which include the spinothalamic
tract, the spinomesencephalic tract, the
spinoreticular system and diffuse polysyn-
aptic connections which relay nociceptive
information within the cord. Descending
tracts arise from the brain stem raphe
nucleus and reticular formation. Descend-
ing inhibition exercises continuous control
of afferent input to the dorsal horn. Both
opioid and nonopioid inhibitory systems
may respond to different types of pain or
stress. The brain stem reticular area trans-
mits all ascending and descending stimuli
(Phillips and Cousins 1986).
Thus, very complex neural connec-
tions involving diverse areas of the nervous
system play a part in pain. Pain may be
modulated at the spinal cord level, in the
periaqueductal grey matter and brain stem
raphe nuclei prior to reaching relays and
gating mechanisms in the thalamus on the
way to the cerebral cortex.
5.1.3 Pain after thoracic surgery
Pain after thoracic surgery can be both
nociceptive and visceral. The pain syndromes
that develop after thoracic surgery take
many forms. Their classification is based on
the origin of pain in specific visceral, mus-
culoskeletal, neural, and dermal tissues (Raj
and Brannon 1993).
Nociceptive pain after thoracic surgery
is due to tissue damage and is mediated
mostly via intercostal nerves from the struc-
tures of the chest wall and most of the
pleura, via the phrenic nerve from the dia-
phragmatic pleura and via the vagal nerve
from the lung and mediastinum including
the mediastinal pleura (Conacher 1990,
Cervero and Laird 1999). Visceral pain after
thoracic surgery is due to pleural irritation
and is mediated from the pleura through
sympathetic nerves to the central nervous
system (Conacher 1990, Cervero and Laird
1999). Thoracic musculoskeletal pain is re-
lated to surgical trauma and postsurgical
changes (Raj and Brannon 1993, Wallace
and Wallace 1997). The most common per-
sistent pain following thoracic surgery is
related to myofascial structures, i.e. muscle,
bone, tendon, and ligament (Raj and
Brannon 1993). Thoracic fascitis following
thoracotomy is also common but the most
common source of myofascial pain is the
muscle (Raj and Brannon 1993, Wallace and
Wallace 1997). Patients can also experience
severe pain caused by chest tubes after tho-
racic surgery if the tubes compress the in-
tercostal nerves. Retractors used in the sur-
gical procedure can cause rib fractures,
which can be very painful and limit respira-
tory function. The intercostal nerves may be
damaged if sutures or wires are passed
around the ribs close to the neurovascular
bundle. Neural pain caused by intercostal
neuralgia following thoracotomy is particu-
larly common. This kind of pain is burning,
lancinating, and aggravated by stretching
the affected nerve and also gets worse at
night (Raj and Brannon 1993). Hyperalge-
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sia is often associated with the wound it-
self. Secondary hyperalgesia possibly results
from central sensitisation. Also, local release
of inflammatory chemical mediators occurs
with tissue damage. These mediators, which
include hydrogen ions, serotonin (5HT), his-
tamine, bradykinin, substance P, prostaglan-
dins, and leukotrienes, have indirect effects
on the nociceptor (Mattison 1990, Dray et
al. 1994). Management of neuropathic pain
requires the tools to identify the mechanism
responsible for the pain in a particular indi-
vidual, and then the capacity to reverse the
mechanisms (Woolf and Mannion 1999).
5.1.4 Degree and duration of pain
after thoracic surgery
The degree of pain after thoracic sur-
gery is generally rated as “severe”. Pain af-
ter thoracotomy has been described as one
of the most severe modes of postoperative
pain (Loan and Morrison 1967, Benedetti
et al. 1984). In a survey performed in the
1960’s in England (Loan and Morrison 1967)
more than 70% of patients required anal-
gesics during the immediate postoperative
period after thoracotomy compared with ap-
proximately 60% after upper abdominal op-
erations and only about 50% after lower
abdominal operations. According to these
authors (Loan and Morrison 1967, Benedetti
et al. 1984) special attention should be given
to the treatment of postoperative pain af-
ter thoracic surgery because of the severity
of the pain. Salzer with colleagues (Salzer
et al. 1997) presented controversial results
concerning the pain after thoracic surgery.
Comparison of postoperative pain during
the first days after posterolateral thorac-
otomy and median laparotomy showed that
the patients undergoing median laparotomy
used significantly more piritramide during
the first 4 postoperative days than the pa-
tients udnergoing posterolateral thorac-
otomy. The VAS scores were also lower in
the thoracotomy group (Salzer et al. 1997).
Published and unpublished data con-
cerning the incidence and duration of pain
compiled by Benedetti with colleagues in-
dicate that postoperative pain occurs more
often and is more severe following intratho-
racic (i.e. thoracotomy or sternotomy) sur-
gery than following orthopaedic or abdomi-
nal surgery. The intensity of steady wound
pain after thoracotomy was severe in 45 –
65% of the patients and moderate in 25 –
35% of the patients. After sternotomy
steady wound pain was severe in 60 – 70%
of the patients and moderate in 25 – 35%
of the patients. After intrathoracic opera-
tions, movements that place tension on the
incision, such as deep breathing, coughing,
or extensive body movements, increase the
intensity of pain. In this survey the average
duration of severe pain was 3 days (range:
2 – 6 days) after thoracotomy and 4 days
(range 2 – 7 days) after sternotomy
(Benedetti et al. 1984).
Less invasive methods of thoracic sur-
gery than open thoracotomy have been
developed during the last 15 years. Patients
undergoing video-assisted thoracic surgery
(VATS), i.e. thoracoscopy, experienced sig-
nificantly less postoperative pain compared
to patients undergoing lateral thoracotomy.
Patients undergoing VATS required less pa-
tient-controlled intravenous morphine ver-
sus patients undergoing lateral thoracotomy.
The postoperative hospital stay was also
shorter after VATS than that required for
patients undergoing lateral thoracotomy
(Landreneau et al. 1993). Patients undergo-
ing axillary thoracotomy have been shown
to have significantly higher pain scores us-
ing VAS than patients undergoing VATS.
Consumption of subcutaneous piritramide,
a synthetic opioid derivative, as an indirect
subjective pain indicator was significantly
higher at all time points in the patients who
underwent thoracotomy (Tschernko et al.
1996).
There are several different incisions used
by surgeons for access to the thorax. Lat-
eral thoracotomy is usually performed at the
level of the fourth, fifth, sixth or seventh rib
spaces and the skin incision may extend
from the second thoracic dermatome pos-
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teriorly to the eighth dermatome close to
the sternum (Conacher 1987). Anterolateral
muscle-sparing thoracotomy has been re-
ported to be postoperatively less painful
than the posterolateral approach (Hazelrigg
et al. 1991). Posterolateral thoracotomy is
the most painful route for surgical access
(Baeza and Foster 1976). Median sterno-
tomy and anterolateral thoracotomy are
notably less painful. Unfortunately, access
to some intrathoracic structures via median
sternotomy is often limited (Baeza and Fos-
ter 1976, de la Rocha and Chambers 1984).
Pain following thoracotomy usually resolves
within two months after surgery. Pain after
thoracic surgery is considered chronic if it
persists for more than two months. Pain that
persists beyond this time or recurs may have
a burning, dysesthetic component (Interna-
tional Association for the Study of Pain,
Subcommittee of Taxonomy 1986a).
5.2 Pain management after
thoracic surgery
5.2.1 Systemic analgesia
Systemic analgesia may be divided into
systemic opioids, nonsteroidal anti-inflam-
matory drugs (NSAIDs), paracetamol and
ketamine. Opioids, NSAIDs, and ketamine
can be delivered using intravenous, intra-
muscular or subcutaneous routes. Patient-
controlled analgesia devices (PCA) can be
useful when administering intravenous
opioids. Combinations of NSAIDs and opio-
ids or opioids and regional analgesia are also
common.
5.2.1.1 NSAIDs
Nonsteroidal  anti-inflammatory  drugs
(NSAIDs) inhibit cyclooxygenase, an enzyme
which controls the synthesis of prostaglan-
dins, prostacyclins, and thromboxanes. All
three may be involved in pain (Juan 1978).
Blockade of pain by NSAIDs is thus a periph-
eral and central action compared with the
predominantly central action of opioids.
NSAIDs including diclofenac, indometha-
cin, ketorolac, lysine acetyl salicylate,
piroxicam, and tenoxicam have been used
as analgesics to reduce pain after thoracic
surgery (Jones et al. 1985, Pavy et al. 1990,
Bigler et al. 1992, Merry et al. 1992, Rhodes
et al. 1992, Kavanagh et al. 1994b, Power
et al. 1994, Singh et al. 1997). Potential ad-
verse effects include gastrointestinal bleed-
ing, acute reversible renal dysfunction and
systemic bleeding associated with platelet
dysfunction irrespective of the route of ad-
ministration (Camu et al. 1992, Kenny 1992,
Johnson et al. 1994, Bugge 1995, Ellenhorn
et al. 1997, Lee et al. 1999). NSAIDs can be
given intravenously, intramuscularly, orally or
rectally (Tigerstedt et al. 1987, Pavy et al.
1990, Kavanagh et al. 1994a, Carretta et al.
1996, Hynninen et al. 2000). There are only
a few NSAIDs which can be delivered
parenterally. In Finland these are diclofenac,
ketoprofen, indomethacin, meloxicam and
ketorolac tromethamine (Laitinen et al. 1992,
Kostamovaara et al. 1998).
Intramuscular diclofenac in a dose of
75 mg every 12 hours for three days as an
adjunct to papaveretum for pain after lat-
eral thoracotomy resulted in lower con-
sumption of papaveretum and in lower vi-
sual analogue scale (VAS) pain scores
throughout the study period compared with
the patients given only papaveretum for
analgesia (Rhodes et al. 1992).
Rectally administered indomethacin re-
duced postoperative VAS pain scores by
60% while the reduction in opioid con-
sumption was approximately 30%. The daily
dose of indomethacin was 200 mg and the
cumulative papaveretum dose in the in-
domethacin group was approximately 70
mg during the first 48 hours. Unfortunately,
PCA was not used for supplementary anal-
gesia and therefore the need for supplemen-
tary analgesics may have been misinter-
preted (Pavy et al. 1990).
Ketorolac has been shown to reduce the
need for patient-controlled epidural analge-
sia (PCEA) with hydromorphone after thora-
cotomy compared with epidural bupivacaine
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while the resting pain scores were compa-
rable in both treatment groups (Singh et al.
1997). I.m. ketorolac as a component of bal-
anced analgesia failed to improve analgesia
after thoracotomy. However, it was difficult
to show any differences in PCA morphine
use or pain scores in this study because of
the large number of patients who withdrew
from the control group (Power et al. 1994).
Continuous infusion of i.v. lysine acetyl
salicylate (7.2 g in 24 h) compared with in-
fusion of i.v. morphine (40 mg in 24 h) has
been shown to be equally effective in treat-
ment of postthoracotomy pain. The VAS
pain scores and PCA papaveretum use were
similar in both groups (Jones et al. 1985).
Intravenous tenoxicam (20 mg) reduced the
consumption of i.v. papaveretum delivered
with a PCA device for postoperative pain
treatment after lateral thoracotomy. The
tenoxicam group used less rescue
papaveretum during the first 12 hours than
the placebo group. There were no signifi-
cant differences between the groups in VAS
pain scores or adverse events (Merry et al.
1992).
Acute renal failure is one of the poten-
tially most serious adverse events associated
with the use of NSAIDs during and after
surgery especially in patients with pre-exist-
ing renal disease or hypovolemia and in
patients taking loop diuretics.
Renal prostaglandins regulate the wa-
ter balance and the excretion of sodium and
potassium. They contribute more to the
maintenance of renal haemodynamics un-
der adverse conditions than under normal
circumstances (Clive and Stoff 1984). There-
fore, inhibition of prostaglandin synthesis
may have profound consequences for renal
blood flow and glomerular filtration rate
when it is superimposed on a preceding
haemodynamic insult e.g. hypovolemia,
hypotension (Henrich et al. 1978), salt
depletion (Blasingham and Nasjletti 1980)
or heart failure (Oliver et al. 1981). Anaes-
thesia and surgery can decrease renal blood
flow as a result of hypovolemia and hy-
potension. Moreover, the stress response
triggered by surgery increases secretion of
antidiuretic hormone (ADH) which normally
stimulates the production of medullary pros-
taglandins. These medullary prostaglandins
can moderate the tubular effects of ADH
by inhibiting the generation of cAMP
(Christensen 1978). NSAIDs have also been
shown to enhance the effects of exogenous
vasopressin (Clive and Stoff 1984).
Increased knowledge about the mecha-
nism of prostaglandin synthesis and the role
of COX isoenzymes has led to the develop-
ment of COX-2 selective nonsteroidal anti-
inflammatory drugs (Jackson and Hawkey
2000). These selective NSAIDs might be
beneficial compared to ordinary NSAIDs
because they may minimise COX-1-depen-
dent adverse events, i.e. gastroduodenal
toxicity, while offering analgesia, a reduc-
tion in opioid requirements, and the poten-
tial to reduce the incidence of chronic pain
after surgery and, possibly, also nausea and
vomiting (McCrory and Lindahl 2002).
Celecoxib showed better tolerability and a
lower frequency of gastrointestinal adverse
events with similar analgesic efficacy com-
pared to diclofenac (Emery et al. 1999). Tang
and co-workers demonstrated a significant
opioid sparing effect with parecoxib, an in-
travenous COX-2 inhibitor, in 55 patients
undergoing lower abdominal surgery (Tang
et al. 2002). On the other hand, these new
COX-2 inhibitors are associated with an in-
creased rate of cardiovascular events, i.e.
myocardial infarctation, unstable angina, and
ischaemic stroke (Mukherjee et al. 2001).
5.2.1.2 Opioids
Postoperative analgesia after thoracic
surgery traditionally consists of intramuscu-
lar, intravenous or subcutaneous administra-
tion of opioids (Gravlee and Rauck 1993).
Opioids including morphine, fentanyl, pe-
thidine  (=  meperidine),  buprenorphine,
piritramide, papaveretum and tramadol have
been used parenterally for pain relief after
thoracic surgery (Shulman et al. 1984,
Sandler et al. 1992, Deneuville et al. 1993,
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Kavanagh et al. 1994a, Slinger et al. 1995,
James et al. 1996, Tschernko et al. 1996,
Salzer et al. 1997). Tramadol is an analgesic
with mixed µ-opioid and nonopioid activ-
ity. The nonopioid component is mediated
through increased α2-agonist and seroton-
ergic activity (Scott and Perry 2000). Intra-
venous opioids can be delivered as bolus
doses or as a continuous infusion. Posttho-
racotomy studies exist on the use of intra-
muscular opioids alone, subcutaneous opio-
ids, nurse-controlled intravenous opioids and
intravenous PCA (Lehmann 1990, Kavanagh
et al. 1994b, Salzer et al. 1997). The main
advantage of i.v. PCA is, that it takes into
sufficient consideration the different subjec-
tive pain sensitivities of each patient (Salzer
et al. 1997). The narrow therapeutic window
is the major problem when using opioids.
Even moderate doses of opioids can result in
adverse effects such as nausea or vomiting,
somnolence and respiratory depression (Jor-
dan et al. 1979). Pulmonary dysfunction is a
major problem especially after thoracotomy.
Multimodal analgesia with morphine
0.15 mg/kg i.m., perphenazine 0.03 mg/kg
i.m. and a rectal suppository of indometha-
cin 100 mg one hour before lateral thorac-
otomy resulted in slightly lower consump-
tion of PCA morphine in the first 6 h after
surgery compared to a control group receiv-
ing midazolam 0.05 mg/kg i.m. preopera-
tively. However, cumulative morphine con-
sumption at 72 h after surgery was greater
in the treatment group (185 mg) compared
with the control group (150 mg) (Kavanagh
et al. 1994b).
Fixed-schedule i.m. buprenorphine (0.3
mg buprenorphine i.m. given every 8 hours
for the first 5 days) was equally effective in
pain relief after thoracotomy compared with
continuous intercostal analgesia with
bupivacaine. Unfortunately, supplementary
analgesics were only given on request and
PCA was not used in this study (Deneuville
et al. 1993).
Subcutaneous piritramide demand was
significantly higher in the patients under-
going thoracotomy compared with patients
undergoing VATS. The injections were given
s.c. as a bolus, using no more than 7.5 mg
piritramide within 45 min (Tschernko et al.
1996).
A single i.v. bolus dose of 150 mg
tramadol provided analgesia which was as
effective as continuous epidural morphine
for a period of 24 hours after thoracotomy.
All patients were provided with an i.v. PCA
device that delivered 1.5 mg bolus doses of
morphine with a lockout time of 8 min
(James et al. 1996). Continuous i.v. tramadol
infusion was shown to be equally effective
as epidural morphine infusion in 30 patients
undergoing posterolateral thoracotomy. All
patients received additional i.v. morphine
boluses in 1.5 mg increments with a PCA
device (Bloch et al. 2002).
5.2.1.3 Ketamine
Ketamine is a non-competitive antago-
nist which blocks the ion channel coupled
to the N-methyl-D-aspartate (NMDA) recep-
tor and hence central hyperexcitability of
dorsal horn neurons. The action of the exci-
tatory amino acids has been extensively
shown to be mediated via the NMDA re-
ceptor and non-NMDA receptors. The
NMDA receptor has been implicated in a
number of long-term events in the central
nervous system (CNS). In vitro studies have
shown that both A-δ and C-fibre activation
increase aspartate and glutamate outflow
at the level of the spinal cord. Activity in
the former, low threshold fibres appears to
normally activate only the alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor. The activities needed for
NMDA-receptor activation are much more
complex and only appear to be achieved by
repeated C-fibre activity (Dickenson 1995).
The effect of a ketamine 0.5 mg/kg
bolus followed by a 20-min infusion of 9
µg/kg/min ketamine on the response to re-
peated nociceptive stimuli (central tempo-
ral summation) was investigated in 12 hu-
man volunteers in an experimental cross-
over study. The reaction time after ketamine
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was significantly (P < 0.01) prolonged com-
pared to placebo. Significant increases in
pain detection and pain tolerance thresh-
olds were found compared with placebo (P
< 0.001). The psychophysical responses, the
summation reflex thresholds, and the VAS
responses to repeated stimuli were changed
significantly by ketamine compared with
placebo (P < 0.001 – P < 0.01). The investi-
gators concluded that ketamine inhibits cen-
tral temporal summation in humans and has
a marked hypoalgesic effect on high inten-
sity nociceptive electrical and mechanical
stimuli (Arendt-Nielsen et al. 1995).
Low-dose i.m. ketamine and i.m. pethi-
dine after thoracic surgery have been shown
to be equally efficacious but there was less
respiratory depression in the ketamine
group. The patients were randomised to
receive an i.m. injection of either pethidine
1 mg/kg or ketamine 1 mg/kg whenever
needed. There were no significant differ-
ences in the pain scores between the two
groups during the study, but the pain scores
tended to be lower in the pethidine group
during the first 2 hours and in the ketamine
group after 3 hours (Dich-Nielsen et al.
1992).
Ketamine has also been used as a part
of multimodal patient-controlled epidural
analgesia. Ketamine added to patient-con-
trolled epidural analgesia (PCEA) resulted in
significantly lower mean VAS scores during
coughing or at rest for the first 3 postopera-
tive days in patients undergoing major sur-
gery. The study included 46 thoracotomy
patients, of whom 26 received a regimen of
morphine 0.02 mg/ml, 0.08% bupivacaine
and adrenaline 4 µg/ml with addition of
ketamine 0.4 mg/ml while 20 received the
same treatment without ketamine. The PCEA
infusion rate and bolus volume was titrated
according to the analgesic effect. The cumu-
lative mean multimodal regimen require-
ments of the control group on days 1 and 2
(96.6 ml and 189.1 ml, respectively) were sig-
nificantly higher than those of the ketamine
group (74.0 ml and 155.4 ml, respectively)
(Chia et al. 1998).
These observations and the laboratory
data concerning the role of N-methyl-D-as-
partate (NMDA) receptor activation in
postinjury central sensitisation and hyperal-
gesia suggest that systemic ketamine, a non-
competitive NMDA-antagonist, may be an
important tool in the treatment of posttho-
racotomy pain (Woolf and Thompson 1991,
Chia et al. 1998, Chow et al. 1998).
5.2.2 Regional analgesia
There are several regional analgesic
methods that can be used for pain manage-
ment after thoracic surgery. These include in-
tercostal, paravertebral, interpleural, epidu-
ral, and spinal blockade. Techniques that have
been described for postthoracotomy analge-
sia include thoracic local anaesthetics, epi-
dural opioids (including opioid agonist-an-
tagonists), thoracic epidural opioids com-
bined with local anaesthetics, thoracic epi-
dural adrenergic agonists, and i.t. opioids.
5.2.2.1 Intercostal blockade
Intercostal blockade has been widely
used for analgesia after thoracic surgery
(Delilkan et al. 1973, Galway et al. 1975,
Kaplan et al. 1975, Toledo-Pereyra and
DeMeester 1979, Asantila et al. 1986, Chan
et al. 1991, Swann et al. 1991, Deneuville
et al. 1993, Dryden et al. 1993). The inter-
costal nerves are the primary rami of spinal
nerves T1 through T11. Somatic innervation
of the area from the nipples to below the
umbilicus is provided by segmental spinal
nerves from T4–T11. The intercostal nerve
has four significant branches. These include
rami communicantes, which pass anteriorly
to and from the sympathetic ganglion and
chain, the posterior cutaneous branch sup-
plying the skin and muscles in the paraver-
tebral region, the lateral cutaneous branch
located in the midaxillary line, and the an-
terior cutaneous branch. The intercostal
nerves lie between the pleura and the fas-
cia of the internal intercostal muscle from
the medial to the posterior angles of the
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ribs. In the paravertebral region, there is only
fatty connective tissue between nerve and
pleura (Kopacz and Thompson 1998).
Local anaesthetics for intercostal block-
ade can be administered as a single bolus
directly before chest closure (Delilkan et al.
1973, Galway et al. 1975, Kaplan et al.
1975, Toledo-Pereyra and DeMeester 1979,
de la Rocha and Chambers 1984), as a single
percutaneous injection (Swann et al. 1991),
as multiple percutaneous injections (Asantila
et al. 1986) or via an indwelling intercostal
catheter (Chan et al. 1991, Deneuville et al.
1993, Dryden et al. 1993). The site of injec-
tion relative to the angle of the ribs and the
attachment of the posterior intercostal
membrane to the internal intercostal muscle
has been shown to be important for the
spread of local anaesthetic solutions (Kopacz
and Thompson 1998). Injections through
intercostal catheters directed medially
spread to 3 to 5 intercostal spaces because
the tips of the catheters end up 2 to 3 cm
medial of the medial border of the
intercostalis intimus muscle, where the so-
lution can freely spread cephalad and
caudad in the extrapleural space where the
parietal pleura is less adherent to the ribs.
Because of the eventual position of these
catheter tips, they are probably more ap-
propriately called ‘continuous paravertebral
catheters’ than ‘continuous extrapleural in-
tercostal catheters’ (Kopacz and Thompson
1998). The main disadvantage of the inter-
costal technique is the high level of systemic
absorption of local anaesthetics (Chan et al.
1991).
Bupivacaine 0.5% 20 ml with adrena-
line 5 µg/ml or normal saline administered
by indwelling intercostal catheter every 6 h
for 24 h after thoracotomy resulted in lower
VAS pain scores after each injection. Opioid
consumption was lower over 24 h in the
bupivacaine group compared to the saline
group (16.6 mg versus 35.8 mg). Repeated
intercostal bupivacaine administration (a
total of 400 mg in 24 hours) led to systemic
accumulation with a peak bupivacaine con-
centration of 1.2 µg/ml, which is below the
toxic range of 4 µg/ml (Chan et al. 1991).
Continuous intercostal bupivacaine for pain
relief after thoracotomy resulted in lower
requirements of i.v. PCA morphine com-
pared with placebo. Patients also recorded
lower VAS pain scores while receiving
bupivacaine. This study was designed as a
crossover trial with patients receiving either
bupivacaine for the first 24 hours and sa-
line for the second or saline for the first 24
hours followed by bupivacaine (Dryden et
al. 1993).
5.2.2.2 Paravertebral blockade
Paravertebral blockade is a unilateral
block suitable for pain treatment after lat-
eral thoracotomy (Sabanathan et al. 1988,
Matthews and Govenden 1989, Sabanathan
et al. 1990, Richardson et al. 1994, Rich-
ardson et al. 1999). The thoracic paraverte-
bral space is continuous with the subpleu-
ral space at the tip of the transverse pro-
cess. Its boundaries include the transverse
process, vertebral body and intervertebral
foramen, costotransverse ligament and
pleura (Kopacz and Thompson 1998,
Karmakar and Chung 2000). The thoracic
paravertebral space is a potential space simi-
lar to the epidural space, filled with fat and
containing both the intercostal nerves and
rami communicantes, and its volume is
much larger than that of the subcostal
space. A thoracic paravertebral block will
result in a regional sympathetic block (Gil-
bert and Hultman 1989). Paravertebral
blockade can be performed either percuta-
neously or intraoperatively under visual con-
trol to avoid complications.
The efficacy of a continuous paraverte-
bral block with 0.5% bupivacaine on
postthoracotomy pain was investigated in
56 patients undergoing thoracotomy.
Paravertebral blockade provided significantly
better pain relief and pulmonary function
with less papaveretum consumption after
thoracotomy during the first 48 hours
(bupivacaine group: 14 mg versus control
group: 136 mg) (Sabanathan et al. 1990).
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Continuous epidural and paravertebral
blocks, commenced before operation as a
part of a balanced analgesic regimen, were
both effective for postoperative pain in pa-
tients undergoing posterolateral thorac-
otomy. However, cumulative morphine con-
sumption in the first and second 24-h peri-
ods was significantly higher in the epidural
group compared with that in the paraverte-
bral group. Patients in the paravertebral
group had significantly lower VAS pain
scores both at rest and on coughing
(Richardson et al. 1999). In a study in 30
patients undergoing anterolateral thorac-
otomy paravertebral and thoracic epidural
analgesia with bupivacaine for postopera-
tive pain treatment were shown to be
equally effective in terms of pain relief and
recovery of pulmonary function. However,
minor differences that would favour paraver-
tebral analgesia were observed (Kaiser et al.
1998). Lignocaine administered for continu-
ous paravertebral nerve blockade after pos-
terolateral thoracotomy has been shown to
produce equally good pain control to
bupivacaine with less risk of systemic toxic-
ity (Watson et al. 1999).
5.2.2.3 Interpleural analgesia
Reiestad and Strømskag (1986) devel-
oped a new method for the treatment of
postoperative pain involving intermittent
administration of local anaesthetics into
the pleural space through an interpleural
catheter which was placed using a percu-
taneous technique. These investigators
presented good results in pain relief in the
patients undergoing cholecystectomy, renal
surgery, and unilateral breast surgery
(Reiestad and Strømskag 1986). Interpleural
analgesia is induced by injecting the local
anaesthetic into the interpleural space which
lies between the parietal and visceral pleu-
rae (Reiestad and Strømskag 1986). The pa-
rietal pleura is in close proximity to the in-
tercostal nerves anteriorly, laterally, and pos-
teriorly. Interpleural analgesia (previously
called intrapleural analgesia) produces re-
gional analgesia of the chest wall and is used
for pain therapy in various indications i.e.
breast, renal, gall bladder surgery, and
chronic pain.
Interpleural analgesia with local anaes-
thetics has also been used for pain relief af-
ter thoracic surgery (Rosenberg et al. 1987,
Symreng et al. 1989, Ferrante et al. 1991,
Mann et al. 1992, Schneider et al. 1993,
Silomon et al. 2000). In this method local
anaesthetic agents can be delivered via an
indwelling interpleural catheter by intermit-
tent (Mann et al. 1992, Schneider et al. 1993)
or continuous infusion (Rosenberg et al.
1987). However, the results of all these stud-
ies are controversial.
Continuous interpleural bupivacaine
administration using the method developed
by Reiestad and Strømskag was unsatisfac-
tory in the management of postoperative
pain after thoracotomy. The initial bolus
dose and the following infusion of 0.5%
bupivacaine were adjusted according to the
patient’s weight (Rosenberg et al. 1987). In
another study, intermittent interpleural
0.25% bupivacaine administered in bolus
doses for 48 – 72 hours after posterolateral
thoracotomy had no effect on total opioid
consumption when the dose of papavere-
tum was adjusted to the weight of the pa-
tients. The bupivacaine group had signifi-
cantly smaller decreases in FVC and FEV1
during the follow-up time. Linear analogue
pain scores showed reduced postoperative
pain in the bupivacaine group at 4, 24 and
72 hours postoperatively compared with the
saline group (Mann et al. 1992). Interpleural
0.5% bupivacaine 30 ml compared with
interpleural saline administered in bolus
doses every 4 h for a total of 12 doses after
posterolateral thoracotomy resulted in no
differences in VAS pain scores or analgesic
requirements. Supplementary morphine or
pethidine was given on demand and no PCA
was used (Schneider et al. 1993). However,
in another study in 83 patients interpleural
bupivacaine analgesia had no influence on
acute postthoracotomy pain. Patients in the
bupivacaine group received 0.5% bupiva-
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caine 20 ml and patients in the placebo
group received the same amount of saline.
Every 4 hours thereafter, each group re-
ceived the same medication 10 times. The
patients were allowed to use i.v. PCA with
piritramide for additional pain relief. Mean
pain scores were significantly reduced 30
min after interpleural instil lation of
bupivacaine or saline. However, there were
no differences between the groups. The
usage of additional piritramide was similar
in both groups (Silomon et al. 2000).
5.2.2.4 Epidural blockade
Local anaesthetics can be used alone or
in combination with opioids for epidural an-
algesia (James et al. 1981, Logas et al. 1987,
Hurford et al. 1993, Kaiser et al. 1998,
Mahon et al. 1999). Epidural analgesia can
be performed using either a lumbar or a tho-
racic approach (Cousins and Veering 1998).
The epidural space surrounds the spinal
meninges and extends from the foramen
magnum to the sacral hiatus. The epidural
space is bounded anteriorly by the poste-
rior longitudinal ligament, laterally by the
pedicles and the intervertebral foramina and
posteriorly by the ligamentum flavum and
the anterior surface of the lamina. In addi-
tion to the nerve roots that transverse the
epidural space, the contents of the epidu-
ral space are fat, areolar tissue, lymphatics,
arteries, and the extensive internal vertebral
venous plexus (Bridenbaugh et al. 1998).
An epidural combination of morphine
plus bupivacaine or epidural morphine alone
in the treatment of postthoracotomy pain
tended to lower self-assessed pain scores
compared with epidural bupivacaine, epi-
dural saline and i.m. morphine (Logas et al.
1987). Epidural infusion was started 30 min
after the induction of anaesthesia at a rate
of 3 ml/h for patients > 60 years of age or
shorter than 168 cm, 4 ml/h for all other
patients. If any patient with epidural infu-
sion complained of postoperative pain, the
rate of the infusion was increased in two
successive 1 ml/h increments to a maximal
rate of either 5 ml/h or 6 ml/h. Continuous
thoracic epidural fentanyl combined with
bupivacaine infusion resulted in a signifi-
cantly lower infusion rate than the rate in
the patients receiving lumbar epidural infu-
sion of bupivacaine and fentanyl after lat-
eral thoracotomy. Both techniques were free
from major complications (Hurford et al.
1993).
With perioperative thoracic epidural
analgesia using a mixture of bupivacaine
0.1% with adrenaline 1:200000 and fenta-
nyl 0.002 mg/ml via the epidural catheter
with an average intraoperative infusion rate
of 7 ml/h (2 – 15 ml/h) postoperative respi-
ratory parameters remained stable and no
opioid-induced respiratory depression was
observed. At the end of surgery PCEA was
instituted utilising the same epidural solu-
tion for postoperative analgesia. No addi-
tional i.v. analgesia was administered. Mi-
nor adverse effects, especially nausea and
vomiting, were seen in less than 15% of
the patients in this follow-up study (Schultz
et al. 1997). Epidural infusion of bupivacaine
10 or 5 mg/h resulted in improved analge-
sia during physiotherapy and a significant
opioid sparing effect (50% decrease) com-
pared with epidural infusion of bupivacaine
1 mg/h or epidural saline. In this double-
blind study (Liu et al. 1995) all patients re-
ceived a PCEA device with fentanyl as
supplementary analgesic.
5.2.2.5 Epidural opioids
Epidural opioids have been adminis-
tered by the thoracic (El-Baz et al. 1984,
Asantila et al. 1986, Logas et al. 1987, Niemi
and Breivik 2001) and lumbar (Sandler et
al. 1986, Sandler et al. 1992) routes. Ana-
tomic sites of opioid analgesic action are
multiple, and include supraspinal areas, the
spinal cord, and injured tissue in the periph-
ery. Systemically administered opioids rap-
idly reach the spinal cord, brainstem, and
brain. Epidural opioids are distributed into
the bloodstream and reach the periphery,
brainstem, and brain in addition to their
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spinal target (Bonnet and Baubillier 1993,
Carr and Cousins 1998). There are reports
showing that epidural and i.v. administra-
tion of morphine produced equivalent post-
operative analgesia (Sandler et al. 1986).
Thoracic epidural morphine administra-
tion resulted in decreased requirements of
morphine and the same degree of analge-
sia when compared with lumbar adminis-
tration in patients undergoing lateral tho-
racotomy (Grant et al. 1993).
In a study by El-Baz (El-Baz et al. 1984)
analgesia was comparable with intermit-
tent administration of 0.5% bupivacaine
through a thoracic epidural catheter and
with continuous infusions or intermittent
bolus doses of thoracic epidural morphine.
In another study lumbar epidural morphine
given in a bolus dose of 5 mg on demand
resulted in significantly lower total doses of
morphine compared with i.v. morphine
given in a dose of 0.05 – 0.07 mg/kg on
demand in treatment of postthoracotomy
pain. The epidural morphine group also had
significantly better pain relief during the
immediate postoperative period up to 8
hours and improved postoperative pulmo-
nary function compared with the i.v. mor-
phine group. Although the mean respira-
tory rate was lower in the epidural group,
significant respiratory depression did not
occur in either group (Shulman et al. 1984).
A dose-response study of lumbar epi-
dural sufentanil bolus doses showed
sufentanil to provide rapid and effective
analgesia, but with a brief duration of ac-
tion. Furthermore, increasing the dose re-
sulted in an increased incidence of respira-
tory depression without any additional an-
algesic benefit (Whiting et al. 1988). It is
noteworthy that sufentanil is the only opioid
which has regulatory approval for epidural
administration. There are however, numer-
ous studies in which epidural administration
of an opioid offered no advantage over the
i.v. route.
Lumbar epidural fentanyl for posttho-
racotomy pain relief provided little if any
advantage over i.v. fentanyl infusion (Sandler
et al. 1992). In another study, epidural pethi-
dine infusion (0.33 mg/kg/h) for pain man-
agement after thoracotomy resulted in sig-
nificantly better postoperative FEV1 and FVC
values than i.v. pethidine infusion (0.33 mg/
kg/h). The epidural group also had signifi-
cantly lower mean VAS scores and lower
total pethidine dosage. Both groups had an
i.v. PCA device which was programmed to
deliver pethidine in 10 mg boluses with a
lockout interval of 5 min (Slinger et al.
1995).
A comparison of thoracic epidural fen-
tanyl with intravenous fentanyl showed that
when fentanyl infusions were titrated to the
patient’s VAS pain ratings, epidural admin-
istration produced similar analgesia to the
intravenous route but with fewer adverse
effects and lower infusion rates. This study
supports the suggestion that administration
of a highly lipid soluble opioid should be
performed in the dermatomal region of the
surgical incision (Salomäki et al. 1991).
Epidural opioids and epidural local
anaesthetics have been combined with the
aim of synergistically blocking spinal noci-
ceptive pathways. Combination of local
anaesthetics and opioids can reduce the
dose-related adverse effects of either class
of agent alone. Several studies have exam-
ined the effectiveness of this technique af-
ter thoracotomy (Logas et al. 1987, Bigler
et al. 1992).
Thoracic epidural bupivacaine plus mor-
phine in combination with rectal adminis-
tration of either piroxicam or placebo re-
sulted in excellent analgesia with similar
needs for supplemental intravenous opioid
analgesics in both groups (Bigler et al.
1992).
In the early postoperative period, the
addition of bupivacaine 0.1% was shown
to improve epidural fentanyl analgesia and
was not associated with the disadvantages
seen with the addition of bupivacaine 0.2%.
VAS pain scores while coughing were sig-
nificantly higher in patients receiving epi-
dural fentanyl alone compared to those pa-
tients receiving additional bupivacaine. The
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need for intraoperative vasopressors and the
incidence of temporary neurological com-
plications were higher in the 0.2%
bupivacaine group (Mahon et al. 1999).
Epidural sufentanil analgesia has been
shown to be optimal for pain treatment af-
ter thoracic surgery when tailored to the site
of nociceptive input and combined with
bupivacaine (Hansdøttir et al. 1996).
5.2.2.6 Intrathecal opioids
Intrathecal opioids have been used as
an adjunct to postthoracotomy analgesia
(Gray et al. 1986, Mason et al. 2001). The
advantages of the technique are simplicity,
reliability and potentially fewer adverse ef-
fects from systemic opioid absorption. I.t.
opioids are carried rostrally in the cerebrospi-
nal fluid and, compared with epidural opio-
ids, enter the peripheral circulation to a
lesser degree (Carr and Cousins 1998). How-
ever, this technique has an increased risk of
respiratory depression and postspinal head-
ache (Cousins and Mather 1984).
Intrathecal injection of 12 µg/kg mor-
phine resulted in significantly lower pain
scores and significantly lower pethidine re-
quirements (59 mg versus 167 mg) com-
pared to control patients treated with i.v.
pethidine after thoracotomy. The conscious-
ness level of the patients in the i.t. group
was higher than in the control group
(Neustein and Cohen 1993). I.t. fentanyl
resulted in a faster onset of analgesia and
significantly lower pain scores at rest, on
coughing and on movement compared with
the control groups after posterolateral tho-
racotomy. The peak expiratory flow rates
were also higher in the i.t. fentanyl group.
All patients were allowed to use i.v. PCA
Mo with a bolus dose of 2 mg and lockout
time of 10 min (Sudarshan et al. 1995).
In patients undergoing thoracotomy i.t.
sufentanil 20 µg combined with Mo 0.2 mg
given after induction of general anaesthesia
resulted in lower pain scores and i.v. PCA Mo
consumption during the first 24 h compared
with the control group (Mason et al. 2001).
In a comparison between i.t. Mo 0.5
mg, 50 µg sufentanil and a combination of
the two i.t. Mo provided better postopera-
tive analgesia than the other two medica-
tions tested, both at rest and on coughing
(Liu et al. 2001). The study was performed
in patients undergoing thoracotomy with
the tested drugs given before general ana-
esthesia.
Serious adverse events associated with
the spinal techniques are high spinal block-
ade or significant systemic toxicity after spi-
nal local anaesthetics, respiratory depression
after spinal opioids (Etches et al. 1989) and
rare cases of spinal cord trauma or nerve
trauma, haematoma, infection or inflamma-
tory reaction associated with the introduc-
tion of catheter or needle (Bridenbaugh et
al. 1998, Carr and Cousins 1998, Cousins
and Veering 1998). Other troublesome ad-
verse effects include nausea, pruritus and
urinary retention after intraspinal opioids
(Bridenbaugh et al. 1998, Carr and Cousins
1998, Cousins and Veering 1998), hypoten-
sion, temporary paralysis, urinary retention
and paraesthesia after intraspinal local
anaesthetics (Bridenbaugh et al. 1998, Carr
and Cousins 1998, Cousins and Veering
1998).
5.2.2.7 Other drugs
Epidural clonidine, an α2-agonist, has
the potential for effective antinociceptive ac-
tivity after systemic or spinal administration
(Maze et al. 1988). The mechanism of ac-
tion appears to be modulation of the en-
dogenous adrenergic receptors in the dor-
sal horn of the spinal cord. However, there
are controversial data regarding the efficacy
of clonidine. The efficacy of a single dose
of thoracic epidural clonidine 3 µg/kg was
compared with saline in a double-blind
study, where no analgesic benefits were
observed (Gordh Jr. 1988). In another study,
addition of 2 µg/kg clonidine to bupivacaine
for intercostal nerve blockade for thorac-
otomy led to a short-term enhancement of
postoperative pain control and improvement
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of arterial oxygenation. Total opioid con-
sumption for the first 24 hours was signifi-
cantly lower for the group which received
clonidine added to a local anaesthetic solu-
tion compared with the clonidine i.m. group
(dose 2 µg/kg) (30 mg versus 41 mg) and
the control group (30 mg versus 47 mg).
Postoperative analgesia was performed with
PCA using piritramide. No significant differ-
ence in total opioid consumption was noted
between the clonidine i.m. group and the
control group during the first 24 hours post-
operatively (Tschernko et al. 1998).
PCEA with morphine plus ketamine may
provide effective analgesia with smaller
doses of morphine and fewer adverse ef-
fects, compared with PCEA with morphine
alone (Tan et al. 1999).
5.2.3 Other methods
Cryoanalgesia involves freezing of an
intercostal nerve by intraoperative appli-
cation of a cryoprobe to its posterior as-
pect, and then allowing the nerve to thaw
(Lloyd et al. 1976, Maiwand and Makey
1981, Maiwand et al. 1986). The procedure
may then be repeated and can be performed
on several nerves in the dermatomal region
of the incision. Because the neurolytic le-
sion produced is partial, and the endoneu-
rium is preserved, axonal regeneration is
possible and normal sensation should return
after surgery (Nelson et al. 1974). Concerns
have been raised about possible long-term
neuralgia (Roxburgh et al. 1987). A two-
group study comparing cryoanalgesia with
a control group that did not receive cryo-
analgesia suggested that there were no ad-
vantages associated with the treatment.
Approximately 20% of the treated patients
developed intercostal neuralgia by 6 weeks
after surgery (Müller et al. 1989). Normal
sensation returns after three to six months
following peroperative cryoanalgesia (Mai-
wand and Makey 1981).
Perioperative cryoanalgesia of the inter-
costal nerves was not shown to be benefi-
cial in the control of postthoracotomy pain.
After discharge from hospital patients were
seen about six weeks and six months after
operation (Roxburgh et al. 1987).
A significant proportion of patients un-
dergoing thoracotomy showed improve-
ment after percutaneous cryotherapy. How-
ever, relief was only temporary and one third
of the patients felt that symptoms were ex-
acerbated by the therapy. The follow-up
time was 3 months (Conacher 1986). In
another study cryoanalgesia provided a
slight improvement in postoperative pain
and analgesic requirements in patients un-
dergoing thoracic surgery but these effects
were not as marked as with high thoracic
epidural infusion of bupivacaine and fenta-
nyl. All patients were allowed i.v. bu-
prenorphine 0.3 mg or propacetamol 1g as
supplementary analgesics (Brichon et al.
1994).
Transcutaneous electrical nerve stimu-
lation (TENS) was introduced into clinical
practice in 1972 as an adjunct to other
therapies. Since then it has been used for
postoperative pain relief, including after
thoracic operations. TENS may produce an-
algesia by modulation of nociceptive input
in the dorsal horn of the spinal cord through
peripheral electrical stimulation of large sen-
sory afferent nerves, the so-called gate con-
trol theory of pain (Wall 1985). Alternatively,
electrical stimulation of certain receptor sites
in the dorsal horn of the spinal cord may
release endorphins. Endogenous opioid and
nonopioid (e.g., γ-aminobutyric acid) me-
chanisms may be involved in mediating
TENS-induced analgesia (Brodsky and Mark
1997). The only significant adverse effects
are local skin hypersensitivity and the possi-
bility that the electrical current could inter-
fere with the function of cardiac pacemak-
ers. On the basis of the available published
data TENS is not a reliable pain relief method
in the treatment of acute postthoracotomy
pain, but can be useful in treatment of
chronic postthoracotomy pain (Stubbing
and Jellicoe 1988, Benedetti et al. 1997a,
Benedetti et al. 1997b, Brodsky and Mark
1997).
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5.3 Respiratory and
cardiovascular effects of
thoracic surgery
Significant changes in pulmonary me-
chanics, gas exchange and control of breath-
ing occur immediately after thoracic surgery
and anaesthesia (Hachenberg and Pfeiffer
1999). Opioids, which are commonly used
for treatment of postoperative pain, sup-
press the spontaneous activity of the respi-
ratory centres thus further decreasing res-
piratory drive (Craig 1981).
The typical respiratory effect after tho-
racic surgery is ventilatory restriction, in
which there is a moderately decreased in-
spiratory volume and vital capacity as well
as a small but important decrease in func-
tional residual capacity. In this situation the
patients breathe rapidly with small tidal vol-
umes and are unable to take deep breaths.
In addition, the patients are unable to cough
properly because of the diminished inspira-
tory capacity (Craig 1981). Immediately af-
ter lateral thoracotomy the reduction in peak
flow rates and timed forced expiratory vol-
umes is of the order of 75% (compared with
preoperative values) (Coleman 1987). If a
restrictive pattern of ventilation with re-
duced lung compliance develops, hypox-
emia may result from shunting of pulmo-
nary arterial blood through atelectatic ar-
eas of the lung leading to ventilation/per-
fusion imbalance (Conacher 1990).
Postoperative disturbances in gas ex-
change have many causes (Hachenberg and
Pfeiffer 1999). Immediately after surgery and
anaesthesia there is hypoxemia lasting from
few minutes up to a couple of hours. This
early hypoxemia is considered to be a con-
sequence of anaesthesia rather than factors
influenced by pulmonary mechanics (Spence
1982). Other possible mechanisms include
alveolar hypoventilation, ventilation/perfu-
sion disturbances, and decreased cardiac
output and increased oxygen consumption
due to increased muscle tone as well as shiv-
ering. The patients with disturbances in gas
exchange are unable to take deep breaths
after surgery. Typical for this disturbance is
hypoxemia without hypercarbia (Craig
1981). However, these effects are not
caused solely by perception of pain. Other
underlying causes include lung trauma, al-
tered architecture, local pulmonary oedema,
increased airways resistance and respiratory
muscle dysfunction (Conacher 1990).
Disturbances in respiratory control in the
immediate postoperative phase are mainly
due to intraoperative anaesthetics includ-
ing drugs used for maintenance of anaes-
thesia and analgesia. Later, opioid analge-
sics used for pain treatment may influence
respiratory control (Catley 1984). If pain
treatment is inadequate, the patient is un-
able to breathe sufficiently deeply (Conacher
1990). Due to shallow breathing some parts
of the lung can collapse leading to
atelectases. At the same time the patient is
unable to cough and the retention of spu-
tum can lead to an increased risk of pneu-
monia (Conacher 1990, Goldstraw 1995).
Hypoxemia leads to global hypoxic pul-
monary vasoconstriction (HPV). This is a physi-
ological mechanism that constricts the pul-
monary vessels in those areas which are not
well ventilated. HPV is mediated by low al-
veolar oxygen tension as well as by low oxy-
gen tension in mixed venous blood. In chronic
pulmonary diseases, HPV is responsible for
cor pulmonale and right ventricular failure
(Enson 1977). After pulmonary resection,
especially after whole lung resection, the to-
tal blood volume perfusing the remaining
lung is relatively increased. The combination
of HPV and increased blood volume over-
strains the right side of the heart and
atrial fibrillation may occur postoperatively
(Currens et al. 1943, Lindgren et al. 1991).
Incidences of atrial fibrillation as high
as 20% have been reported after left sided
thoracotomies. Prophylactic verapamil and
digitalis therapy has been shown to protect
the right ventricle against HPV and prevent
atrial tachyarrhythmia in the immediate
postoperative period (Lindgren et al. 1991).
Myasthenia gravis patients often un-
dergo sternotomy when their thymus is re-
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moved for treatment of the disease. These
patients are particularly vulnerable to ad-
verse respiratory events postoperatively as
their respiratory muscles are often weak and
the pulmonary reserves diminished. In ad-
dition, myasthenia gravis patients are ex-
tremely sensitive to respiratory depression
associated with opioids, which explains why
postoperative pain treatment can be prob-
lematic in these patients (Baraka 1992).
5.4 Chronic pain after
thoracotomy
Persistent postthoracotomy pain is com-
mon but its true incidence is difficult to as-
sess (Jackson 1993). The reported incidence
is 29 – 67% (Matsunaga et al. 1990, Perkins
and Kehlet 2000), of which only 25% is
severe (Kanner et al. 1982). Long-term post-
thoracotomy pain has been reported after
surgery for both malignant as well as be-
nign disease (Kanner et al. 1982, Dajczman
et al. 1991). In thoracotomy patients with
malignancy, however, the duration of post-
operative pain was found to last longer
(Kanner et al. 1982). Decreased severity of
chronic pain has been reported after VATS
when compared with lateral thoracotomy
(Landreneau et al. 1994) and after postero-
lateral thoracotomy the severity of chronic
pain is increased when compared with an-
terolateral thoracotomy (Nomori et al. 1997,
Benedetti et al. 1998). Patients undergoing
VATS appear to have less subjective shoul-
der dysfunction than patients undergoing
thoracotomy (Landreneau et al. 1994). There
is little data available concerning the rela-
tionship between the immediate postopera-
tive pain treatment and long-term
postthoracotomy pain (Katz et al. 1996,
Obata et al. 1999).
The morbidity and the nature of residual
pain after thoracotomy for malignant and
benign disease was investigated in 90 pa-
tients 6 – 18 months after the thoracotomy.
Two patients in three complained of
postthoracotomy pain for up to 6 months,
but 75% of these patients regarded their
pain as mild and needed no medication. The
residual pain persisted longer in patients
with malignancies, in patients aged over 50
years and in patients who needed analge-
sics for more than two postoperative weeks
(Matsunaga et al. 1990).
The predictors of the postthoracotomy
pain syndrome (PTPS) when tumour recur-
rence is excluded include the extent of acute
postoperative pain and intercostal nerve
dysfunction. These results are based on a
computerised search of the medical litera-
ture covering the entire database from 1966
through most of 1998 concerning chronic
pain as an outcome of surgery. Only thora-
cotomy studies with more than 50 patients
per study were included in this analysis. In
addition, the studies had to contain data
about persistent pain (12 weeks or more
after surgery). Six thoracotomy studies ful-
filled these inclusion-exclusion criteria. These
studies assessed together 878 patients, of
whom 417 (47%) had PTPS (Perkins and
Kehlet 2000).
An incidence of 26% (n = 126) for per-
sistent or recurrent pain has been reported
in a prospective follow-up study after tho-
racotomy. During the monthly follow-up for
over 8 months the pain had disappeared at
5 months in 79 patients but returned in 13
patients while in 20 patients the pain actu-
ally increased in severity. The pain was
caused by either tumour or infection (Kanner
et al. 1982).
In another study with a median follow-
up time of 19.5 months (2 months – 5 years)
the incidence of long-term postthoracotomy
pain was reported to be 54%. Pain inten-
sity was mostly low but 23% of the patients
stated that pain interfered with their life to
some extent. Persistent pain appeared to
decrease with time. One year after surgery
its incidence was 55% whereas two years
after surgery it was 45% and more than
three years after surgery it had decreased
to 38% (Dajczman et al. 1991).
In a small, but well designed prospec-
tive study of pre-emptive, multimodal anal-
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gesia Katz and co-workers reported long-
term pain in 52% of the patients who had
undergone lateral thoracotomy 1.5 years
earlier. The patients were interviewed by
telephone using a standardised question-
naire. The typical description was of a dull,
aching or burning pain situated in the chest
wall. Early postoperative pain was the only
factor that significantly predicted long-term
pain. Pain intensity on the first day after
surgery, both at rest and after movement,
was significantly greater among patients
who developed long-term pain compared
with those who did not. Cumulative Mo
consumption was identical for the two
groups, indicating that differences in pain
were not mediated by postoperative anal-
gesic usage (Katz et al. 1996).
Postthoracotomy pain may also be of
nonneuropathic origin. In a retrospective
study 27 patients with PTPS were followed
in a pain clinic. The first consultation about
the patient’s pain was on average 75 days
after surgery. Mechanical allodynia was seen
in 41% and hypesthesia in 93% of patients.
Two types of trigger points were found; the
first, adjacent to the wound, was observed
in 44% of the patients, while the second,
observed in 67% of the patients, was in the
scapular region in a taut muscular band. The
trigger point in a taut muscular band met
the clinical criteria of myofascial pain and it
was effectively treated with injections us-
ing local anaesthetics (Hamada et al. 2000).
The effect of a continuous epidural
block initiated before thoracic surgery on
early and long-term pain was investigated
in a double-blind study in 70 patients un-
dergoing posterolateral thoracotomy. After
induction of anaesthesia the patients were
randomly allocated to one of the two
groups. In the preoperative group, 4 ml
mepivacaine 1.5% was administered
epidurally 20 min before the surgical inci-
sion, followed by a continuous infusion at
4 ml/h until 72 hours after surgery. For the
postoperative group the procedure was the
same except that the first 4-ml dose was
administered at completion of the opera-
tion. If pain relief was inadequate 50 mg
indomethacin p.r. was administered on re-
quest. No other analgesics were adminis-
tered. The VAS scores at rest were lower in
the preoperative group at four hours after
surgery and on the second and third post-
operative days. There was no difference
between the groups in the usage of rectal
indomethacin up to the seventh postopera-
tive day. The percentages of pain-free pa-
tients were higher in the preoperative group
at three and six months after surgery (Obata
et al. 1999).
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6 AIMS OF THE STUDY
The aims of the present study were
1. To investigate the incidence, severity and duration of acute postthoracotomy
pain (I).
2. To compare the efficacy and adverse events of intravenous morphine, nonsteroidal
anti-inflammatory analgesics and three different regional anaesthetic methods in
pain relief after two types of thoracic surgery (II, III, IV).
3. To compare the efficacy and adverse events of intravenous and intrathecal mor-
phine in pain relief after transsternal thymectomy in myasthenia gravis patients (V).
4. To investigate the incidence, duration, severity and risk factors of persistent
postthoracotomy pain (I, VI).
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7 PATIENTS AND METHODS
in question were examined to determine the
amount of analgesics the patients were pre-
scribed and how much they actually received
during the first two postoperative days. Of
the total of 214 medical records, seven were
excluded because the patient had either
died or had renewed surgery within the first
2 postoperative days. A letter was sent to
150 surviving patients (Table 1). The char-
acteristics of all patients are shown in Table
2. A total of 136 patients entered studies II
– V. Eleven patients were excluded from
studies II – V mostly for technical reasons
(Table 3).
Table 1: Number of patients in study I
Patient documents studied 214
Patients excluded (reoperation or death within first 2 postoperative days) 7
Medication analysed 207
Questionnaire sent 150
Questionnaire answered 134
% of patients answered the questionnaire 89%
7.1 Patients
A total of 442 patients were examined
in six different studies. The 207 patients re-
ported in paper I had undergone thoracoto-
mies at Helsinki University Central Hospital
during 1986 – 1988. The 110 consecutive
patients reported in paper VI underwent
elective thoracotomy at Helsinki University
Central Hospital during 1991 – 1994. The
125 patients participating in the studies re-
ported in papers II – V underwent thoracic
surgery at Helsinki University Central Hos-
pital during 1989 – 1996.
In study I, the charts of all 214 patients
undergoing thoracotomy during the period
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Tab
le 2:
D
em
o
g
rap
h
ic d
ata o
f all p
atien
ts in
 stu
d
ies I – V
I
The data is presented as arithm
etic m
eans (range).
Paper I II III IV V VI
Study design Retrospective randomised, randomised, randomised, randomised, prospective,
double-blind, open, double-blind,  open, follow-up
placebo parallel-group placebo controlled,
controlled, controlled, parallel-group
parallel-group parallel-group
Number of patients 207 30 45 30 20 110
Female/male 69/138 6/24 23722 16/14 17/3 45/65
Age (y) 57.2 57.2 (23–75) 51.5 (23–72) 45.3 (18–70) 35.2 (16–81) 56.3 (19–77)
Weight (kg) 71.9 74.8 (40–105) 75.8 (52–112) 76.0 (56–116) 68.5 (50–110) 73.3 (44–127)
Height (cm) NA 174 (159–185) 171(154–196) 170 (155–189) 167 (150–182) 169 (148–190)
ASA I–IV I–III I–III I–III II–III I–IV
Duration of operation (min) NA 112 (30–205) 91 (25–205) 58 (20–265) 78 (48–170) NA
Type of operation
Pneumectomy 42 5 3 – – 21
Lobectomy 151 17 17 – – 34
Biopsy, resection 13 8 25 30 – 55
Thoracolaparotomy 1 – – – – –
Thymectomy – – – – 20 –
Malignant disease 84% 80% 51% 17% 0% 57%
Benign/malignant disease NA 6/24 22/23 25/5 20/0 47/63
NA = not available
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In studies II – V, patients with clinically
manifest cardiac, hepatic or renal failure
were excluded, as well as patients with al-
lergy to morphine or the study drugs i.e. lo-
cal anaesthetics or nonsteroidal anti-inflam-
matory analgesics. Mentally confused pa-
tients were also excluded from the studies.
In studies II – V, the patients had to be ASA
Physical Status I – III. In studies II – IV, the
patients had to be younger than 75 years.
In study II I, patients scheduled for
pleurectomy or unable to cooperate, pa-
tients with a neurological disease or infec-
tion at the operation site and patients who
had a preoperative forced expiratory volume
(FEV1) of less than 60% of the reference
value were also excluded. In studies II and
IV, patients with a history of gastrointesti-
nal bleeding or peptic ulceration,
haemorrhagic diathesis or asthma were ex-
cluded. In study II the estimated postopera-
tive FEV1 had to be > 1.0 l/sec. In study III,
patients with a preoperative FEV1 below 60%
of the reference value, indicating severe pul-
monary dysfunction, and patients with
known sleep apnoea were also excluded as
well as patients with back complaints or skin
infections in the lumbar region.
Twenty patients with a diagnosis of
myasthenia gravis who were scheduled for
Table 3: Patient numbers in studies II – V
Study no. II III IV V
No. of patients entered the study NA 51 35 20
No. of patients analysed 30 45 30 20
No. of patients excluded from the study NA 6 5 0
massive haemorrhage 1 2 –
catheterization unsuccesful 2 – –
unable to cooperate 1 – –
severe nausea before operation 1 – –
study infusion stopped too early – 1 –
difficulties with oxygenation during the operation – 1 –
operation type changed 1 1 –
NA = not available
transsternal thymectomy were included in
study V. The diagnosis of myasthenia gravis
had been confirmed by a typical history,
characteristic neurophysiologic findings
(EMG), the presence of acetylcholine recep-
tor antibodies (anti-AChR-ab) and/or posi-
tive response to edrophonium. Acetylcho-
line receptor antibodies were determined by
radioimmunoassay (Lefvert et al. 1978).
Titres, expressed as arbitrary units l –1 were
considered abnormal when over 0.2. In ad-
dition, all patients had undergone human
leukocyte antigen (HLA) typing. The clinical
severity of myasthenia gravis was deter-
mined using a modified Osserman’s classifi-
cation after testing the fatigability of differ-
ent muscle groups (Oosterhuis 1984). Anti-
cholinesterase medication was withdrawn
12 h preoperatively and started again 24 h
postoperatively.
In study VI, 110 patients were inter-
viewed one day before elective thoracic sur-
gery. The patients also completed a ques-
tionnaire 5 – 7 days after surgery. A stan-
dard mail interview was performed 3, 6 and
12 months after surgery. Reminders were
posted two weeks after the first letter if
necessary. All consecutive patients were
studied except those who died within one
week after surgery (Table 4).
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Patients having an epidural or a paraver-
tebral catheter or PCA for postoperative pain
treatment as well as those who were reop-
erated within one week were excluded from
the analgesic usage part of the study. How-
Preoper 1 week 3 months 6 months 1 year
No. of patients who returned the questionnaire 110 100 87 77 67
No response 0 4 11 13 15
No. of patients alive 110 104 98 90 82
Exitus (cumulative count) 0 6 12 20 28
Total 110 110 110 110 110
% of patients who answered the questionnaire
(calculated from patients alive) 100% 96% 89% 86% 82%
% of patients who died 0 5% 11% 18% 25%
Table 4: Patient numbers in study VI
Table 5: Pain treatment analysis in study VI
1 week 3 months 6 months 1 year
No. patients alive 104 98 90 82
No. of patients who returned the questionnaire 100 87 77 67
Patients having
PCA 10 10 9 9
epidural 1 1 1 1
reoperation within 1 week 1 1 0 0
reoperation within 1 week + PCA 1 1 1 1
reoperation within 1 week and paravertebral 1 1 1 1
Subtotal 14 14 12 9
Total no. of patients possible to analyse for pain
treatment 86* 73 65* 58
Total no. of patients analysed for pain treatment 83* 63*
* Results for totals may not agree with results for individual cells because of missing values for split
variables (patients have not answered the questionnaire properly)
ever, their data were used to analyse the
incidence of chronic postthoracotomy pain.
The pain treatment of 83 patients was
analysed (Table 5).
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7.2 Study designs
Study I was a retrospective question-
naire study evaluating the incidence and
treatment of both acute and persistent
postthoracotomy pain. Study VI was a fol-
low-up study assessing the incidence, du-
ration and severity of persistent postthora-
cotomy pain. Study III was a randomised,
open study designed to assess the efficacy
and adverse effects of three different local
anaesthetic methods in postoperative pain
relief after thoracotomy. Studies II and IV
were randomised, double-blinded, placebo-
controlled trials. They were designed to as-
sess the efficacy and adverse events of non-
steroidal anti-inflammatory drugs in pain
relief after thoracic surgery. Study V was a
randomised, open study designed to assess
the efficacy and adverse events of i.t. Mo in
pain relief after sternotomy in patients with
myasthenia gravis.
7.3 Anaesthesia (studies II–V)
Due to the retrospective nature of study
I details of premedication and anaesthesia
could not be obtained from the source data
of the patients. In study VI choice of the
method of premedication and anaesthesia
was left to the discretion of the anaesthe-
tist in charge of the patient. The routine
method of postoperative pain relief con-
sisted of intraoperative intercostal blockade
with bupivacaine and postoperatively
administered parenteral opioids and non-
steroidal anti-inflammatory drugs when
needed. Patient-controlled analgesia and
epidural/paravertebral analgesia were also
used, but only in a few patients.
In the interventional studies II – V intra-
muscular Mo was used as premedication
about 1 h before surgery (studies II – IV: 0.13
mg/kg, study V: 0.1 mg/kg). Anaesthesia was
standardised in studies II – V. Peroperative
monitoring consisted of intra-arterial pres-
sure, pulse oximetry and end-tidal CO2. In
study V electromyography and hand skin
temperature were also monitored. Glyco-
pyrrolate 0.2 mg i.v. (study II: 4 µg/kg) was
administered immediately before induction.
After precurarisation with pancuronium bro-
mide (15 µg/kg) general anaesthesia was in-
duced with fentanyl (0.003 mg/kg) (studies
II – IV) or alfentanil (1 – 2 mg) (study V) and
thiopentone. Succinylcholine (1.5 mg/kg) was
given to facilitate endobronchial intubation
(Robertshaw® or Bronchocath® tubes in stud-
ies II – IV). The patients in studies II – IV re-
ceived fentanyl only at the induction of ana-
esthesia and thereafter no additional opio-
ids were given during anaesthesia, which was
maintained with 50% (studies II – III) or 60%
nitrous oxide (study IV) and 1 – 3% enflurane
in oxygen. In study V anaesthesia was main-
tained with 66% NO2 in O2 without inhala-
tional anaesthetics and additional doses of
alfentanil (0.5 – 1 mg) were given if needed
up to the start of the closure of sternotomy.
In studies III and IV the inspired oxygen con-
centration was increased to 100% during
one-lung ventilation and in study II accord-
ing to arterial blood-gas analysis to maintain
adequate oxygenation. End-tidal carbon di-
oxide (ETCO2) was monitored continuously
and arterial blood samples for determination
of arterial blood-gas analyses were obtained
at least every 30 min to maintain normo-ven-
tilation. Anaesthesia and postoperative pain
treatment of all patients were managed by
the same anaesthesiologists (K.P. in study II
and III, K.P. or E.N. in study IV, K.P. and E.N.
in study V).
Muscular  relaxation  was  achieved
with pancuronium bromide and monitored
visually using a peripheral nerve stimulator
(studies II – IV). At the end of anaesthesia
the residual muscle relaxation was
antagonised with neostigmine 2 mg and
glycopyrrolate 0.4 mg i.v.
In study V neuromuscular function was
monitored by EMG of the adductor pollicis
muscle (train-of-four stimuli at 20-sec inter-
vals; Relaxograph™ Datex, Finland). In this
study an individual dose-response curve for
vecuronium was established (Nilsson and
Meretoja 1990). At the end of surgery the
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neuromuscular block was antagonised with
neostigmine 0.06 mg/kg together with
glycopyrrolate 0.008 mg/kg divided into
three doses and given at 5-min intervals. The
patients were extubated when the EMG
showed complete recovery and the patients
fulfilled the extubation criteria (Gorback
1990).
In studies II and III pulmonary surgery
was performed through a standard antero-
lateral thoracotomy via the 5th intercostal
space. In study IV pulmonary surgery was
performed using standard thoracoscopy pro-
cedures. Three intercostal ports (diameter 5
– 12 mm) were used for insertion of the
thoracoscope and the instruments into the
pleural cavity (Salo 1994).
7.4 Treatment of post-
operative pain (studies II–V)
In study II the patients were randomly
allocated to receive either a diclofenac or a
placebo infusion in a double blind fashion
and the infusion was started immediately
after the patient had arrived in the recovery
room. In study IV the patients were ran-
domly allocated to receive a diclofenac, a
ketorolac or a placebo infusion in a double
blind fashion. In this study the infusion was
started approximately one hour before ana-
esthesia. A recovery room nurse who was
not otherwise involved in the study prepared
the infusions. All infusions were given via
an infusion pump (study II: Oximetrix Inc.,
Mountain View, Ca.; study IV: Terufusion
Syringe Pump Model STC521, Terumo© Cor-
poration, Tokyo, Japan).
In studies II and IV the diclofenac infu-
sion (1 mg/ml in 0.9% NaCl) was started
with a bolus dose (in study II 25 ml in 15
min and in study IV 17 ml in 30 min) and
continued with a constant rate infusion of
2 ml/kg/24 h for 48 h. The maximum daily
dose of diclofenac was 150 mg. In study IV
ketorolac infusion (0.6 mg/ml in 0.9% NaCl)
was started with a bolus dose of 17 ml (=
10 mg) in 30 min and continued thereafter
at a constant rate of 2 ml/kg/24 h for 48 h.
The maximum daily dose of ketorolac was
90 mg. Placebo infusion (0.9% NaCl) was
performed in the same manner, the patients
first receiving bolus doses of 25 ml in 15
min (study II) or 17 ml in 30 min (study IV)
and the infusion then being continued at a
constant rate of 2 ml/kg/24 h for 48 h.
In study III, the patients were randomly
allocated to three groups: intercostal, epi-
dural or paravertebral. In the intercostal
group, intrathoracic unilateral intercostal
nerve blocks (T3 – T7) with a total of 16 ml
0.5% bupivacaine were performed by the
surgeon at the end of the operation before
wound closure. In the epidural group a tho-
racic 20-gauge epidural catheter was intro-
duced preoperatively between the 5th and
6th or 6th and 7th spinal processes through
an 18-gauge needle (epidural catheter set;
Portex®, Hythe, Kent, U.K.) using the mid-
line technique. The correct location of the
catheter was confirmed with 4 ml of 2%
lignocaine. In the paravertebral group the
surgeon placed a paravertebral catheter (epi-
dural catheter set; Portex® Hythe, Kent, U.K.)
intraoperatively. Before closure of the tho-
racotomy wound the catheter was inserted
into the pleural cavity percutaneously via an
18-gauge needle at the midclavicular line
in the second intercostal space. The pari-
etal pleura was opened (length 1 cm) over
the sympathetic trunk at the level of the 3rd
rib and an extrapleural pocket fashioned
between the posterolateral pleura and the
chest wall. It extended from the posterior
wound margin on the vertebral bodies to
two intercostal spaces above and two be-
low the thoracotomy incision. The catheter
was fixed with absorbable suture material
(Catgut; Ethicon®, Norderstedt, Germany)
close to the sympathetic trunk and the open-
ing in the parietal pleura was closed.
The patients in the epidural and paraver-
tebral groups in study III received bolus doses
of 0.25% bupivacaine according to height
(8 ml for 150 – 160 cm, 10 ml for 161 –
180 cm and 12 ml for over 180 cm) before
wound closure and a continuous infusion
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of 0.25% bupivacaine (4 ml/h for 150 – 160
cm, 6 ml/h for 161 – 180 cm and 8 ml/h for
over 180 cm) was started immediately after
the patient had arrived in the recovery room.
The infusion was continued for 48 h using
an infusion pump (IVAC Syringe Pump
Model 700; IVAC© Corporation, San Diego,
CA, USA). In 10 patients in the epidural
group and 8 patients in the paravertebral
group the position of the catheter was de-
termined by X-ray with contrast medium (4
ml Omnipaque 300 mg/ml, Nycomed Im-
aging AS, Oslo, Norway).
In study V the patients were randomised
to two groups for postoperative pain relief:
an intrathecal morphine group (i.t. Mo) and
a PCA morphine group (PCA Mo). In the i.t.
Mo group the patients were given 10 µg/
kg of preservative-free morphine diluted in
2 ml of saline intrathecally before induction
of anaesthesia. The injection was performed
at the L3 – L4 interspace with a 25 or a 27-
gauge Quincke type spinal needle with the
patient in a sitting position.
In studies II – V, all patients were also
allowed to take supplementary doses of
morphine (study II: 10 mg/ml, study III – V:
2 mg/ml) intravenously from a patient-con-
trolled analgesia (PCA) device. In study II the
PCA-device (Prominject®; Pharmacia AB,
Sweden) was programmed as follows: a
bolus dose of 3 mg given over 1 minute
followed by a tail dose of 2 mg (continuous
infusion of morphine for 60 minutes). The
lock out time was 30 minutes. The time
points of the self-administered morphine
doses were recorded. In studies III – V the
PCA-device (Graseby Medical; Graseby
Medical Ltd, Colonial Way, Watford, Herts,
UK) was programmed to provide a bolus
dose of 30 µg/kg corresponding to 2.1 mg
of morphine in a patient weighing 70 kg.
The lock out time was 5 – 10 min (study IV)
or 7 – 10 min (study III, V) up to the first
postoperative morning and thereafter 10 –
12 min (study IV), 12 – 15 min (study III) or
15 min (study V). All patients spent the first
postoperative night in the postoperative
anaesthesia care unit (PACU).
In study II the surgeon performed the
intrathoracic intercostal nerve blockades (Th
3 – 7) with 16 ml 0.5% bupivacaine before
wound closure. If the morphine dose deliv-
ered by the PCA-device was not sufficient
for pain relief 5 mg of morphine was given
intramuscularly.
7.5 Measurement of pain
Visual analogue scales (VAS) (studies II –
V), four point verbal rating scales (VRS: none
= 0, mild = 1, moderate = 2 or severe = 3)
(studies II – IV), five-point verbal rating scales
(none = 0, mild = 1, moderate = 2, severe =
3, excruciating = 4) (study VI) and the McGill
pain questionnaire (study VI) were used for
pain measurement. For better display of the
visual pain intensity scale, a ruler 50 cm long
and 10 cm wide with an increasing red area
representing pain intensity and a centimetre
scale on the back was used (Tigerstedt and
Tammisto 1988). In the postoperative pain
assessment period, this ruler was shown to
the patient from a distance of about 30 cm
and the patient asked to indicate with his
finger the intensity of his or her pain. The
idea behind the VAS and the ruler was ex-
plained to the patient preoperatively. In this
report of the studies the VAS scores are pre-
sented as percentages of the maximum value
on the visual analogue scale.
In study II, the patients were asked to
assess the intensity of wound pain at rest
using a VAS and the intensity of shoulder
pain using a VRS. In study III, the patients
were asked to assess the intensity of pain at
rest and when coughing using a VAS and
VRS. In study IV, the patients were asked
about the intensity of wound pain at rest,
when moving and when coughing using
both VAS and VRS. In study V, only a VAS
was used to assess the wound pain. The
schedule of the examinations is presented
in Table 6. It can be seen that there is a long
break in the measurements between 6 and
20 hours postoperatively which can be ex-
plained by the fact that it was usually the
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same person who performed the measure-
ments. Additionally, it should be mentioned
that due to the timing of the operations,
the 6-h measurement was usually performed
at 6 p.m. on the day of the operation and
the 20-h measurement at 8 a.m. on the first
postoperative morning.
In study III, the upper and lower sen-
sory levels of analgesia were assessed by pin
prick sensation on both sides. The most cau-
dal and the most cranial dermatomes insen-
sitive to the stimuli were recorded. An ob-
server who was blind as to which infusion
the patient was receiving interviewed the
patients in studies II and IV. In study VI all
patients were interviewed one day before
surgery to determine if they had preopera-
tive pain and to familiarise them with the
pain measurement questionnaire. Standard
methods, i.e. the 5-point verbal rating scale
and the McGill pain questionnaire, were
used. Patients filled in the pain question-
naire again 5 – 7 days after surgery to evalu-
ate the immediate postoperative pain. The
patients were interviewed by a standard let-
ter 3, 6 and 12 months after surgery. Re-
minders were posted two weeks after the
first mailing if necessary.
7.6 Measurement of
respiratory, renal and
haematological effects
The patients received 28% or 35% oxy-
gen supplementation through a venturi
mask until at least 6 hours postoperatively
(study IV) or until the first postoperative
morning (studies II – III, V). Arterial blood
gas analysis was performed in studies II–V
up to the second postoperative day. The
arterial oxygen pressure values were divided
by the inspiratory oxygen fraction (PaO2/
0.35) to allow the comparison of values
obtained during various oxygen supplemen-
tation methods (study II). The schedule of
measurements concerning respiratory sta-
tus is presented in Table 7.
Oxygen saturation was monitored con-
tinuously by pulse oximetry (SpO2) using a
finger probe up to the first postoperative
morning. In studies III – V forced expiratory
volume in 1 s (FEV1) and forced vital capac-
ity (FVC) were measured with a pocket
spirometer (Micro Spirometer; Micro Medi-
cal Limited, Rochester, Kent, England). The
patient was in a semirecumbent position
during measurements and the baseline val-
ues were obtained the day before surgery.
Respiratory rate (RR) was recorded in stud-
ies II – V.
Table 6: Schedule for the assessment of pain in studies II – V
Time point
Study II × × × × × × × × × × × × × × × ×
Study III × × × × × × × × × × ×
Study IV × × × × × × × × × ×
Study V × × × × × × × × × × × ×
0 30
 m
in
1 
h
1.
5 
h
2 
h
3 
h
4 
h
5 
h
6 
h
8 
h
20
 h
24
 h
28
 h
30
 h
32
 h
42
 h
44
 h
48
 h
52
 h
56
 h
39
In studies II and III, urine output was mea-
sured up to the second postoperative morn-
ing. If the patients had no spontaneous urine
output the bladder was catheterised on the
first postoperative morning (studies II and III)
and, where needed, on the first postopera-
tive evening (study II) or on the second post-
operative day (studies II and III).
Crystalloids were infused up to the first
postoperative morning in all interventional
studies (II – V). In study IV crystalloid solu-
tions were given via an infusion pump in a
dose of 40 ml/kg. In studies II and V the
amount of crystalloids infused up to the first
postoperative morning was not pre-deter-
mined in the study protocol. In study III the
amount of crystalloids was fixed at 30 ml/
kg but the solutions were not given using
an infusion pump.
Blood loss during the surgical procedure
and postoperatively through the drains was
measured (studies II – V). Any loss less than
400 ml (study II) or 500 ml (study III – V)
was replaced with hydroxyethyl starch
(Plasmafusin 6%®, Kabi Pharmacia AB, Swe-
den) and any loss exceeding 400 ml (study
II) or 500 ml (study III – V) was replaced with
packed red cells.
Safety laboratory assessments were per-
formed in studies II – IV according to the
schedule presented in Table 8. The effect of
i.v. NSAIDs on bleeding time and blood co-
agulation when administered over 48 hours
was of particular interest in studies II and
Table 7: Respiratory measurements in studies II – V
Study II
Radiospirometry ×
Chest X-ray × × × ×
Arterial blood gas analysis × × × × × ×
Respiratory rate × × × × × × × × × × × ×
SpO2 × × × × × × ×
Study III
FEV1, FVC (pocket spirometry) × × × × × × × × ×
Chest X-ray × × ×
Arterial blood gas analysis × × × × × × × ×
Respiratory rate × × × × × × × × × × ×
SpO2 × × × × × × × × × × ×
Study IV
FEV1, FVC (pocket spirometry) × × × × × × ×
Chest X-ray × ×
Arterial blood gas analysis × × × × × × × ×
Respiratory rate × × × × × × × × ×
SpO2 × × × × × × × × ×
Study V
FEV1, FVC (pocket spirometry) × × × × × × × × × × × × ×
Chest X-ray × (×)
Arterial blood gas analysis × × × × × × × ×
Respiratory rate × × × × × × × × × × × × × ×
SpO2 × × × × × × × × × × × × × ×
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IV. IVY bleeding time (Simplate-II®; General
Diagnostics, Warner-Lambert Co., Morris
Plains, New Jersey) was assessed in studies
II and IV always by the same person.
The platelet adhesion test (Adeplat S®;
Platelet Adhesion Test Set, Semmelweis S.r.l.,
div. Mascia Brunelli; Milano, Italy) was per-
formed using an in vitro technique in which
a certain amount of native blood is passed
through a set of glass micro-beads (studies
II and IV). The rate of blood flow through
the column was kept constant by the use
of an infusion pump (Adeplat Pump Sys-
tem). All parameters which influence the
retention of platelet by the glass were
standardised (Hellem 1970).
Thromboelastography (TEG) (Throm-
belastograph D; Hellige GmbH, Freiburg im
Breisgau, Germany) was also performed.
Samples were citrated whole blood (studies
II and IV). Coagulation was initiated by add-
ing calcium chloride to the cuvettes. TEG
tracings were analysed by measuring reac-
tion time (R, min), coagulation time (K/R+K,
min) and maximum amplitude (MA, mm)
(Spiess et al. 1988, Kuitunen et al. 1991).
Table 8: Schedule for laboratory assessments in studies II – IV
Study II
Hb, Hct × – × – × × ×
Serum creatinine × – – – × – –
Platelet count × – × × × × ×
IVY bleeding time × – × × × × ×
Adeplat, TEG × – × –
Study III
Hb, Hct × × – – × × –
Serum creatinine × – – – × × –
Study IV
Hb, Hct × × – – × × –
Serum creatinine × × – – × × –
Platelet count × – × – × – –
IVY bleeding time × – × – × – –
Adeplat, TEG × – × – × – –
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7.7 Measurement of drug
plasma concentrations
Plasma drug concentrations were mea-
sured in studies III, IV and V. The analyses
were performed by the laboratory of the De-
partment of Clinical Pharmacology at Uni-
versity of Helsinki.
In study III, arterial blood samples for
assay of plasma bupivacaine concentrations
were drawn into siliconised tubes before and
10, 30 and 60 min and 2, 4, 6 and 24 h
after the bolus dose of bupivacaine in all
groups and, in addition, 48 h after the op-
eration in the paravertebral and epidural
groups. Plasma bupivacaine concentrations
were determined by high-performance liq-
uid chromatography (Lindberg and
Pihlajamäki 1984). Samples were extracted
with diethylether. Demethyldoxepin was
used as internal standard. The chromato-
graphic system consisted of a C-8 reversed
phase column and the mobile phase was
acetonitrile – 0.05 mol/l phosphate buffer
pH 3.3 (30:70 v/v). The concentration range
was linear between 0.020 – 1.5 µg/ml. The
coefficient of variation for inter-assay deter-
minations was 3.8% (n = 16) at a concen-
tration of 1.18 µg/ml.
In study IV, arterial blood samples for
assay of plasma diclofenac and ketorolac
concentrations were drawn into siliconised
tubes before and after the 30 min bolus in-
fusion and 30 min, 2, 6, 10, 16, 24 and 48
h after the start of the continuous infusion.
Plasma concentrations of diclofenac were
determined with high-performance liquid
chromatography using electrochemical de-
tection (Zecca et al. 1991). Flufenamic acid
was used as internal standard. Samples were
chromatographed in a C-18 inverse phase
column. The limit of quantitation in the
plasma diclofenac analysis was 0.03 mg/l. The
coefficient of variation for inter-assay deter-
minations was 1.8% (n = 7) at a concentra-
tion of 0.13 mg/l, 5.43% (n = 7) at a con-
centration of 1.3 mg/l and 1.44% (n = 7) at
a concentration of 5.4 mg/l. Plasma concen-
trations of ketorolac were determined with
high-performance liquid chromatography
using electrochemical detection (Jones and
Bjorksten 1994). Naproxen was used as in-
ternal standard. Samples were chromato-
graphed on a C-18 inverse phase column.
The limit of quantitation in the plasma
ketorolac analysis was 0.05 mg/l. The coef-
ficient of variation for inter-assay determi-
nations was 3.5% (n = 7) at a concentra-
tion of 0.08 mg/l, 1.9% (n = 7) at a con-
centration of 0.8 mg/l and 4.1% (n = 7) at
a concentration of 4.0 mg/l, respectively.
In study V, plasma concentrations of
morphine were determined with high-per-
formance liquid chromatography using elec-
trochemical detection (Zoer et al. 1986).
Dihydromorphine was used as internal stan-
dard. Samples were chromatographed in a
straight phase system with a silica column.
The concentration range was linear between
2 – 40 ng/ml. The coefficient of variation
for inter-assay determinations was 13.5%
(n = 22) at a concentration of 8 ng/ml. In
the PCA-group plasma concentrations of
morphine were measured on arrival in the
PACU, and 10 min, 30 min, 60 min, 4 hrs
and 24 hrs later. In the i.t. Mo group the
first plasma concentration of morphine was
measured before administration of i.t. Mo
followed by measurements 10 min, 30 min,
60 min, 4 hrs and 24 hrs later. The total
follow-up period was 48 hours.
7.8 Postoperative evaluation
of adverse events and
performance status
On the first and second postoperative
days the patients in studies II – IV were evalu-
ated for adverse effects (i.e. drowsiness,
confusion, nausea, vomiting, itching, ab-
dominal pain, dizziness, hallucinations, dif-
ficulties with breathing or allergic reactions)
or any other symptom that either the pa-
tient or personnel considered important to
notify. In study II the axillary temperature
was measured preoperatively and on the
first, second and third postoperative days
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at 4 p.m. At the same time the patients were
asked to rate their performance status i.e.
sleeping, mobility, drinking, eating and
bowel function, using a scale of: absent (0),
moderately impaired (1) or normal (2) (study
II) or absent (0), moderately impaired (1),
slightly impaired (2) or normal (3) (studies
III – IV).
7.9 Questionnaire studies
In study I the charts of all 214 patients
who had undergone thoracotomies in the
IIIrd Department of Surgery, Helsinki Univer-
sity Central Hospital, during 1986–1988
were examined to establish the amounts of
analgesics the patients were prescribed and
the amounts of analgesics they eventually
received during the recovery room period
and during the first and second postopera-
tive days on the ward. Nurses’ notes were
analysed for comments on postoperative
pain.
A letter was also sent to the 150 surviv-
ing patients asking them to answer the fol-
lowing questions:
1. Would you rate the pain you experi-
enced during the first week after your
operation in spite of the painkillers that
you were given as minor, considerable
or excruciating?
2. Was the pain relief you were given
good, satisfactory or poor?
3. If you were not satisfied with the pain
treatment, would you have wished for
higher doses of analgesics, shorter in-
tervals between doses, local anaesthetic
blocks or something else (please spe-
cify)?
4. Did you have pain at home?
5. If you had pain at home, did it last for
less than 3 months, between 3 and 6
months or for more than 6 months?
6. Do you still have pain that you think is
due to the operation?
7. Have you received any treatment for
your pain?
8. If you have received treatment, have you
been given ordinary pain killers, strong
analgesics, other drugs, local anaes-
thetic blocks, acupuncture, cryotherapy,
physiotherapy or something else (please
tick as appropriate and specify if neces-
sary)?
9. Could you please indicate the painful
area on the enclosed diagram using the
following symbols to describe the type
of pain: xxx = ache, ooo = burning pain,
=== = tenderness and III = numbness.
One hundred and ten patients undergoing
elective thoracotomy participated in study
VI. The amounts of analgesics the patients
received were recorded during the first 5
postoperative days. To enable comparison
of different analgesics, all opioids were con-
verted to equianalgesic doses of morphine
using the ratios presented in Table 9.
Morphine 10 mg
Oxycodone 10 mg
Pethidine 75 mg
Buprenorphine 0.3 mg
Codeine 130 mg
Dextropropoxyphene 300 mg
Table 9: Equianalgesic doses of opioid
analgesics for postoperative pain treat-
ment used in study VI
The doses of the nonsteroidal anti-inflam-
matory drugs (NSAIDs) are presented in
Table 10 as fractions of the recommended
maximum daily doses for postoperative pain
treatment. If a formulation containing both
an opioid and an NSAID was used, both in-
gredients are shown.
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7.10 Ethical considerations
The Institutional Ethics Committees of
the Department of Anaesthesia and Depart-
ment of Cardiothoracic Surgery at Helsinki
University Central Hospital approved the
study protocols. Informed consent was ob-
tained from all patients in studies II – VI.
7.11 Statistical analysis
A nurse who was in no way involved in
the studies performed the randomisation
using sealed envelopes. In the double-blind
studies the code was opened after the clini-
cal phase of the study. In drug concentra-
tion analyses the laboratory personnel was
blinded to the samples.
Demographic data was evaluated with
Student’s t-test (study I – II, VI), with the
Kruskal-Wallis (study III – IV) and with the
Mann-Whitney test (Study V) where appro-
priate.
A two-way analysis of variance for re-
peated measures and Scheffe’s method
(study II – IV) or Fisher’s PSLD test (study V)
for testing all contrasts were used for the
Acetylsalicylic acid 3000 mg
Paracetamol 3000 mg
Diclofenac sodium 150 mg
Indomethacin 150 mg
Ibuprofen 2400 mg
Ketoprofen 300 mg
Ketorolac tromethamine 90 mg
Tolfenamic acid 600 mg
Metamizole 4000 mg
Table 10: Equianalgesic doses of NSAIDs
for postoperative pain treatment used
in study VI
evaluation of VAS data and consumption
of morphine (studies II – V), VRS, (studies II
– IV) PaO2/FiO2, PaCO2, IVY-bleeding times
and platelet counts (study II, IV), bupivacaine
concentrations and forced expiratory vol-
ume in 1 s (FEV1) (study III, V) and morphine
plasma concentrations and FVC (study V)
followed by the Mann-Whitney U-test (study
II, V) or the Kruskal-Wallis test (study III)
at individual time points, where needed
(Table 11).
In study IV, a factorial analysis of variance
was used for the statistical analysis of mor-
phine consumption after logarithmic transfor-
mation of the data followed byt-tests at
individual time points where needed.
Urine output, plasma creatinine, blood
loss, platelet count (studies II – IV) and plate-
let adhesion test values (study II, IV) were
analysed in study II using the Mann-Whitney
U-test for unpaired data and with the
Wilcoxon signed rank test for paired data
and in studies III – IV with the Kruskal-Wallis
test.
In study V, linear regression analysis was
performed to evaluate the relationship be-
tween duration of the disease (yrs), preop-
erative dose of pyridostigmine (mg), anti-
AChR-ab-titres (arbitrary units l–}1) and indi-
vidual ED95 dose of vecuronium.
The incidence of adverse events (study
II – V) and the performance status (study III)
were compared using the chi-square test. P
< 0.05 was considered statistically signifi-
cant (studies II – III).
In study I, the consumption of analge-
sics, estimations of pain and pain relief were
compared with the Mann-Whitney’s U-test,
Kruskal-Wallis and Spearman rank correla-
tion test. In study VI, the consumption of
analgesics and the degree of pain were
analysed by factorial ANOVA. The calcula-
tions were performed using the commer-
cially available statistical program StatView
512+ or 4.0 for Macintosh.
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Table 11: Statistical analysis
Study I Study II Study III Study IV Study V Study VI
Demographic data t-test t-test Kruskal-Wallis Kruskal-Wallis Mann Whitney t-test
VAS, VRS 2-way ANOVA for 2-way ANOVA and 2-way ANOVA for 2-way ANOVA and
repeated Scheffe’s method repeated Fisher’s PSLD test and
measurements followed by Kruskal- measurements and Mann-Whitney
followed by Mann- Wallis, when needed Scheffe’s method
Whitney when
needed
Consumption 2-way ANOVA for 2-way ANOVA and Factorial ANOVA with 2-way ANOVA and
of morphine repeated Scheffe’s method lognormal Fisher’s PSLD test and
measurements followed by Kruskal- transformation and Mann-Whitney
followed by Mann- Wallis, when needed Scheffe’s method
Whitney when followed by t-test,
needed when needed
Urine output, plasma Mann-Whitney U-test Kruskal-Wallis Kruskal-Wallis
creatinine, blood loss, for unpaired data and
platelet Wilcoxon signed rank
test for paired data
Adhesion test values Mann-Whitney U-test Mann-Whitney U-test
for unpaired data and for unpaired data and
Wilcoxon signed rank Wilcoxon signed rank
test for paired data test for paired data
Relationship between duration Linear regression
of the disease (yrs), preoperative analysis
dose of pyridostigmine (mg),
anti-AChR-ab-titres (arbitrary
units l–1) and individual ED95
dose of vecuronium
Adverse events Chi-square test Chi-square test Chi-square test Chi-square test
Performance status Chi-square test
Consumption of analgesics, Mann-Whitney U-test, Factorial ANOVA
estimation of pain and pain Kruskal-Wallis and
relief (I) or degree of pain (VI) Spearman rank
correlation test
A two-way analysis of variance for repeated measures and Scheffe’s method (study II-IV) or Fisher’s PSLD test (study V) for testing all contrasts were used for the statistical analysis
of VAS and consumption of morphine (studies II-V), VRS, (studies II-IV) PaO2/FiO2, PaCO2, IVY-bleeding times and platelet counts (study II, IV), bupivacaine concentrations and
forced expiratory volume in 1 s (FEV1) (study III, V) and morphine plasma concentrations and FVC (study V) followed by Mann-Whitney U-test (study II, V) or the Kruskal-Wallis test
(study III) at individual time points, when needed.
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8 RESULTS
8.1 Pain intensity and
analgesic consumption as a
measure of pain
Consumption of morphine in control
patients was somewhat lower after thora-
coscopy than after thoracotomy. After ster-
notomy consumption of morphine was even
lower than after thoracoscopy (Table 12 and
Figure 1). In the two thoracotomy studies II
and III PCA morphine consumption in the
placebo groups during the first 48 hours was
comparable (mean: study II 137.6 mg vs.
study III 119.7 mg).
Table 12: Morphine consumption in control patients (studies II – V)
Cumulative Cumulative
consumption of consumption of
morphine after first morphine after first
24 hours 44 hours
Study no
(additional treatment) Median Range Median Range
Study II (intercostal) 70.1 24–156 135.3 35–238
Study III (intercostal) 70.0 24–137 104.0 36–209
Study IV (–) 59.3 12–124 82.8 16–178
Study V (–) 44.8 14–158 60.2 14–214
Figure 1: Consumption of morphine after different types of operations
(control patients)
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In studies I and VI, consumption of opio-
ids during the first two postoperative days
was lower than in studies II – V. In study I
cumulative opioid consumption during the
first 24 hours was 57 – 61% less than in
the thoracotomy studies II – III. In study VI
cumulative opioid consumption was 9 –
18% less than in the thoracotomy studies II
– III (Table 12 and Table 13).
The VAS-ratings in the control patients
after different types of operations are pre-
sented in Figure 2 as percentages of the
maximum value on the VAS scale (VAS%).
There was a significant difference in VAS%
between the control patients in studies III
and IV (P < 0.05) on the first postoperative
day and also in studies IV and V (P < 0.05) 6
h after the surgery and on the first postop-
erative day. There was no difference in
VAS% between the patients treated with
diclofenac for postoperative pain in studies
II and IV despite different types of opera-
tion (thoracotomy vs. thoracoscopy) and
usage of intraoperative intercostal block in
study II (Figure 3). In study II, the patients in
the control group experienced significantly
more wound pain compared with the
diclofenac group during the immediate
postoperative period (up to 120 min) (p <
0.05) and on both postoperative mornings.
On the first postoperative morning signifi-
cantly less (p < 0.05) shoulder pain was ex-
perienced in the diclofenac group.
Table 13: Opioid consumption during first 2 days in studies I and VI
Cumulative Cumulative
consumption of opioids consumption of opioids
during first 24 hours during first 48 hours
Median Range Median Range
Study I (N = 207) 46 10–138 81 10–188
Study VI (N = 63) 30 0–158 62 7–170
Figure 2: VAS% after different types of operations in control patients
(studies II – V)
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The postoperative VAS pain intensity
scores at rest (VASpi) in the control patients
in study III were on average 48% of the
maximum value whereas in study IV the av-
erage score was 34% (Figure 2). On the first
postoperative morning the VASpi at rest was
22% in study III compared with 9% in study
IV. The pain scores were even higher when
the patient moved (scores at 24h postop-
eratively: study III 47% vs. study IV 21%) or
coughed (scores at 24-h postoperatively:
study III 62% vs. study IV 23%) (Figure 4
and Figure 5). In study III, the patients re-
ported similar levels of pain at rest. In the
epidural group, however, the patients ex-
perienced significantly more pain when
coughing compared with the intercostal
group in the immediate postoperative pe-
riod (up to 4 h) (Figure 4). In study V, the
postoperative pain scores at rest were com-
parable in the i.t. and i.v. Mo groups start-
ing with an average score of 60% of the
maximum immediately after surgery and
decreasing to 19% of the maximum in 24
hours. The difference in the intensity of pain
between the study groups did not increase
statistically significantly during the first post-
operative day although in the i.t. group 4
patients had postdural puncture headache
that exceeded the wound pain in severity.
Figure 3: VAS% in patients treated with diclofenac (studies II and IV)
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In study I, 134 surviving patients (i.e.
89%) answered the letter and returned the
questionnaire. Of these patients 44% re-
ported that they still had pain which they
related to the thoracotomy. There were no
comments in 30% of the patients’ charts
concerning postoperative pain during the
two postoperative days on the wards. The
charts showed that 10% of the patients had
no pain, 40% had pain while severe pain
was reported in 20%.
In study VI, 50% of the patients had no
pain when admitted home, 37% had pain
up to 3 months, 6% for 3 to 6 months, 3%
for more than 6 months and 4% could not
answer. In this study 17% of all the patients
had had pain preoperatively. Neither the
incidence nor the severity of chronic pain
differed between the patients with malig-
nant and benign disease. Both the incidence
and the severity of chronic postthoracotomy
pain decreased with time (Table 14).
Figure 4: VAS% in Study III
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8.2 Analgesic efficacy
Only the patients in studies I and VI had
intramuscular opioids for pain relief. The dis-
tribution of opioid consumption during the
recovery room period and the 1st and 2nd
postoperative days is shown in Figure 6. In
study I, there was a statistically significant
correlation between the consumption of
opioids in the recovery room and during the
1st postoperative day and between the
opioid consumption during the 1st and the
2nd postoperative days. Oxycodone was
administered to all patients except to two,
who were given morphine as the primary
postoperative opioid. In addition, bupre-
norphine was given to 13 patients (6%) and
pethidine to 5 patients (2%). In study VI all
patients except two received opioids dur-
ing the first postoperative day. Most of the
patients received oxycodone as the primary
opioid analgesic. The amounts of opioids
received by the patients are presented in
Table 15.
Table 14: Incidence and severity of pain in study VI
1 week 3 months 6 months 1 year
postoperatively
n = 97 n = 84 n = 75 n = 62
Count Percent Count Percent Count Percent Count Percent
Severity of pain
No pain 5 5 17 20 19 25 24 39
Mild pain 38 39 38 45 34 45 28 45
Moderate pain 39 40 25 30 20 27 7 11
Severe pain 14 14 3 4 2 3 3 5
Excruciating pain 1 1 1 1 0 0 0 0
Figure 5: VAS% in thoracotomy patients (studies II – III)
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Table 15: Opioids given in studies I and VI
All patients Patients with persistent Patients without persistent
postthoracotomy pain postthoracotomy pain
Study I N = 207 N = 59 N = 75
Median dose of oxycodone (mg)
(range) given
In the recovery room 9 (0–88) 9 (0–44) 8 (0–50)
1st postoperative day 40 (0–90) 40 (12–80) 40 (7–90)
2nd postoperative day 32 (0–70) 36 (0–70) 36 (0–70)
Cumulative first 2 days 81 (10–188) 86 (12–145) 84 (10–140)
Study VI N = 63 N = 17 N = 46
Median dose (mg) (range) of
opioids given
In the recovery room 7 (0–52) 10 (0–52) 6.5 (0–27)
1st postoperative day 16 (0–70) 14 (0–70) 17 (0–58)
2nd postoperative day 36 (0–118) 40 (0–118) 35.5 (0–62)
Cumulative first 2 days 62 (7–170) 79 (34–170) 61 (7–117)
Figure 6: Oxycodone consumption during the first 2 days in studies I and VI
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Table 16: Morphine consumption in thoracotomy studies II and III
Cumulative amount of morphine
during first 44 hours after surgery
Median Range
Study II
Placebo 135.3 35.0 – 238.4
Diclofenac 39.0 10.0 – 105.3
Study III
Intercostal 104.0 35.6 – 208.6
Epidural 110.0 39.6 – 196.9
Paravertebral 80.9 46.4 – 195.9
In all other studies (studies II – V), the
patients were allowed to take supplemen-
tary doses of morphine via a PCA device. In
study II, consumption of PCA Mo was sig-
nificantly less in the diclofenac group com-
pared with the control group during both
the first 20-h study period (CI95 13.3 – 34.2;
mean 23.7 mg vs. 45.5 – 86.4; mean 66.0
mg; p = 0.002) and the first 44-h study pe-
riod (CI95 28.5 – 62.9; mean 45.7 mg vs.
95.8 – 157.2; mean 126.5 mg; p = 0.0001).
Three patients in the diclofenac group and
nine patients in the control group required
i.m. Mo injections to supplement PCA Mo.
The consumption of morphine decreased
significantly from the first to the second
postoperative day in the diclofenac group
(p < 0.05), but not in the control group. In
study III, there were no significant differ-
ences in morphine consumption between
the groups (epidural, paravertebral, and in-
tercostal) (Table 16).
In study IV, the cumulative consumption
of PCA Mo was significantly less in the
diclofenac and ketorolac groups compared
with the placebo group from 16 h to 44 h
after surgery (p < 0.05). The 95% confi-
dence intervals (CI95) for cumulative mor-
phine consumption 20 h after surgery were
33.2 – 81.7 (mean 57.4 mg) in the placebo
group, 11.9 – 30.0 (mean 21.0 mg) in the
diclofenac group and 8.4 – 54.8 (mean 31.6
mg) in the ketorolac group. The CI95s for
cumulative morphine consumption 44 h
after the operation were 54.3 – 129.1 (mean
91.7 mg) in the placebo group, 16.4 – 53.5
(mean 34.9 mg) in the diclofenac group and
10.9 – 76.3 (mean 43.6 mg) in the ketorolac
group.
In study V, the PCA Mo group required
significantly more i.v. Mo than the i.t. Mo
group (p < 0.05) during the first 12 postop-
erative hours. At 12 h the mean cumulative
morphine consumption in the PCA Mo
group was 30 mg (range 6 – 112.6 mg,
median 24.6) compared with a mean of 10
mg (range 0 – 30.2 mg, median 8.4) (p <
0.05) in the i.t. Mo group. The 95% confi-
dence intervals (CI95) for cumulative mor-
phine consumption 20-h after the opera-
tion were 15.4 – 74.4 (mean 44.9 mg) in
the PCA Mo group and 11.7 – 31.7 (mean
21.7 mg) in the i.t. Mo group. The CI95s for
cumulative morphine consumption 44-h
after the operation were 23.4 – 113.4 (mean
68.4 mg) in the PCA Mo group and 25.1 –
61.0 (mean 43.0 mg) in the i.t. Mo group.
The duration of analgesia in the i.t. Mo
group, determined as the time elapsed from
induction to the first supplemental PCA
morphine dose, was on average 6 hours
(range 2 – 22 hours).
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Cumulative morphine consumption in
patients treated with diclofenac for postop-
erative pain after thoracotomy and thora-
coscopy in studies II and IV was comparable
(Figure 7). In all studies the lowest consump-
tion of morphine was detected in patients
treated with NSAIDs (i.e. diclofenac or
ketorolac) (Figure 8). The mean differences
in consumption of morphine in studies II –
IV are presented in Table 17.
Figure 8: Consumption of morphine in all interventional groups (studies II – V)
Figure 7: Consumption of morphine in patients given diclofenac
(studies II and IV)
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8.3 Safety variables
8.3.1 Respiratory status
In study II arterial oxygenation was sig-
nificantly greater in the diclofenac group
compared with the placebo group at 4, 6
and 20 hours with oxygen supplementation
and at 20.5 h without oxygen supplemen-
tation. There were no significant differences
in the actual PaCO2 values between the
groups, but the mean increase in PaCO2
from the preoperative values to those at 20
h was significantly greater (P < 0.05) in the
placebo group (20 (3.3)%) compared with
the diclofenac group (7.5 (4.1)%). No
atelectasis was seen in any of the postop-
erative chest x-rays.
In study III, there were no significant
differences between the groups in respira-
tory rate, arterial oxygen tension (PaO2),
Table 17: Mean differences in consumption of morphine in studies II – IV
Mean 95% 95% P
difference Lower Upper
Study III intercostal vs. study II diclofenac 64.0 31.6 96.5 0.0003
Study III intercostal vs. study IV diclofenac 72.0 33.5 110.6 0.0004
Study III intercostal vs. study IV ketorolac 61.6 18.1 105.0 0.0021
Study III epidural vs. study II diclofenac 70.6 37.6 103.6 < 0.0001
Study III epidural vs. study IV diclofenac 78.6 39.3 117.9 0.0001
Study III epidural vs. study IV ketorolac 68.1 24.0 112.2 0.0007
Study III paravertebral vs. study II diclofenac 49.5 22.3 76.8 0.0055
Study III paravertebral vs. study IV diclofenac 57.5 26.3 88.7 0.0044
Study III paravertebral vs. study IV ketorolac 47.1 9.6 84.6 0.019
Study II diclofenac vs. study II placebo –80.8 –115.0 –46.6 < 0.0001
Study II diclofenac vs. study IV placebo –47.5 –84.0 –11.0 0.0222
Study II placebo vs. study IV diclofenac 88.8 47.8 129.7 < 0.0001
Study II placebo vs. study IV ketorolac 78.3 32.7 123.9 0.0001
Study IV diclofenac vs. study IV placebo –55.5 –97.8 –13.2 0.0151
SpO2 or the percentage change in FEV1 from
the preoperative value. In study IV, the
groups were comparable with regard to
changes in FVC and FEV1. There were no
significant differences in PaO2 or PaCO2 val-
ues between the groups.
In study V the FVC values, when com-
pared with the baseline values, recovered
better in the i.t. Mo group than in the PCA
Mo group during the first 24 hours (p < 0.05).
FVC% was 60 ± 8% at 8h in the i.t. Mo
group while the corresponding value in the
PCA Mo group was 33 ± 5.2% (p < 0.05).
FEV1 was less suppressed when compared
with the baseline measurements in the i.t.
Mo group than in the PCA Mo group at 6,
20 and 24h (p < 0.05). FEV1% at 6 h was
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Figure 9: Change in FEV1% in the i.t. Mo and the PCA Mo groups (study V)
Figure 10: Decrease in FEV1 after different types of operations (control patients)
62.2 ± 7.3% in the i.t. Mo group compared
with 37 ± 4% (p < 0.05) in the PCA Mo group
(Figure 9).
The decrease in FEV1 after different types
of operations, i.e. thoracotomy, thoracoscopy
and sternotomy, is presented in Figure 10.
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Table 18: Diuresis in studies II – IV
Urine output (ml) Urine output (ml) Crystalloid solutions
1. postoperative day 2. postoperative day given (ml/kg)
1st day after operation
Study II
Diclofenac 41 1220 33 (2)
[0–400] [700–2200]
Placebo 230 1268 35 (2)
[0–850] [350–2050]
Study III
Intercostal 565 1211 N.A.
[50–1050] [600–2700]
Epidural 574 1280 N.A.
[125–1300] [800–2150]
Paravertebral 601 1296 N.A.
[100–1040] [350–2100]
Study IV
Diclofenac 653 1645 41 (1.8)
[30–1700] [700–3150]
Ketorolac 508 2331 41 (0.8)
[50–1300] [1100–3450]
Placebo 772 2224 37 (1.3)
[100–1600] [1300–3300]
N.A. = not available
8.3.2 Urine output and kidney
function
In study II there were no statistically sig-
nificant differences in the creatinine-values
between the groups either pre- or post-
operatively. Urine output was significantly
lower in both groups on the first post-
operative day than on the second post-
operative day (p < 0.01). Urine output dur-
ing the first postoperative day was signifi-
cantly lower (p < 0.05) in the diclofenac than
in the control group. There were no signifi-
cant differences in the amounts of crystal-
loids infused between the two groups.
In studies III and IV there were no sta-
tistically significant differences in the crea-
tinine values, in the urine output during the
first and second postoperative days, or in
the amounts of crystalloids infused between
the different groups (Table 18).
8.3.3 Haematological variables
The prestudy values for the platelet ad-
hesion test, Ivy bleeding time, platelet count
and thromboelastography variables were
comparable in the different groups in stud-
ies II and IV and did not differ significantly
between or within the groups at the vari-
ous time points, with the exception of the
platelet count, which decreased with time
in study II in both groups (Table 19, Table
20, and Table 21).
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Table 20: Adeplat (%) in studies II and IV
Mean (SD) Preop. 2 h 24 h
II Diclofenac 99.2 (1.3) 99.5 (0.6) –
II Placebo 98.7 (2.3) 98.5 (2.4) –
IV Diclofenac 96.2 (5.0) 91.6 (21.2) 95.1 (6.5)
IV Ketorolac 94.8 (5.4) 95.1 (4.3) 95.0 (2.4)
IV Placebo 91.8 (7.6) 95.1 (5.0) 96.8 (3.7)
Table 19: Blood loss in studies II – IV
Mean [range] Peroper Day 1 Day 2
II Diclofenac 423 480 351
[100 – 1300] [100 – 850] [0 – 650]
II Placebo 570 535 365
[0 – 2700] [110 – 1900] [50 – 900]
III Intercostal 168 487 323
[0 – 400] [200 – 1760] [50 – 1000]
III Epidural 283 463 338
[0 – 1200] [160 – 1100] [20 – 900]
III Paravertebral 163 415 299
[0 – 650] [130 – 700] [20 – 520]
IV Diclofenac 7.5 116 –
[0 – 50] [0 – 200]
IV Ketorolac 20 123 –
[0 – 100] [20 – 350]
IV Placebo 20 139 –
[0 – 150] [25 – 300]
Table 21: IVY bleeding time (min) in studies II and IV
Mean (SD) Preop. 2 h 24 h 48 h 72 h
II Diclofenac 6.0 (2.3) 5.7 (1.2) 6.4 (2.1) 6.0 (2.5) 5.4 (2.2)
II Placebo 5.5 (1.2) 5.3 (1.9) 5.4 (1.8) 5.1 (1.7) 5.2 (1.7)
IV Diclofenac 6.3 (1.9) 5.2 (1.7) 6.2 (1.9) – –
IV Ketorolac 5.6 (2.4) 6.1 (2.1) 6.7 (2.0) – –
IV Placebo 5.7 (1.2) 5.7 (1.2) 4.8 (1.5) – –
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8.3.4 Plasma drug concentrations
8.3.4.1 Bupivacaine
In study III the plasma concentrations
of bupivacaine differed significantly be-
tween the groups. Up to 2 hours after the
block, bupivacaine concentrations were
higher in the intercostal group than in the
epidural or paravertebral group. Bupivacaine
concentrations were significantly lower in
the intercostal group than in the two other
groups from 6 h after the block. There ap-
peared to be a wider range in the
bupivacaine concentration in the paraver-
tebral group than in the other two groups
(range at 48 h: paravertebral 0.45 – 5.1 µg/
ml vs. epidural 0.38 – 1.88 µg/ml; range at
10 min: intercostal 0.19 – 1.46 µg/ml).
8.3.4.2 NSAIDs
The individual plasma concentration
curves for diclofenac and ketorolac in study
IV are presented in Figure 11. The interindi-
vidual variation in the time-concentration
curves was somewhat greater in the ketorolac
group than in the diclofenac group.
Figure 11: Individual plasma concentrations of NSAIDs in study V
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8.3.4.3 Morphine
In study V the plasma concentrations
of morphine differed significantly between
the groups up to 4 h postoperatively. At this
time they were 7.2 ± 4.2 ng/ml in the i.t.
Mo group vs. 18.8 ± 3.9 ng/ml in the PCA
Mo group (p < 0.03).
8.4 Adverse events of
analgesic therapy
There were no significant differences in
adverse events between the groups in stud-
ies II – IV. In study V the incidence of ad-
verse events was comparable in both
groups, except that on the first postopera-
tive day nausea combined with headache
(p < 0.05) and itching (p < 0.05) differed
statistically between the groups (Table 22).
In study II, 13 patients in the diclofenac
group and 9 patients in the control group
had a urine output below 100 ml during
the first postoperative day, but no signifi-
cant difference could be detected between
the groups (Table 18).
In study III 4 patients in the epidural
group, 3 in the paravertebral group and one
patient in the intercostal group had serious
respiratory depression (PaCO2 > 8 kPa = 60
mmHg) more than 2 h after surgery. Six
patients (2 in the intercostal group, 3 in the
paravertebral group and one in the epidu-
ral group) had moderate respiratory depres-
sion (PaCO2 7 – 8 kPa = 52 – 60 mmHg). Six
of these 14 patients were obese and 2 of
them had a history of hypertension. Nine of
these patients had consumed 1.5 – 2 times
the mean dose of morphine. In four of the
patients there was no obvious explanation
for the respiratory depression.
In study V PaCO2 was slightly elevated
in both groups. The samples for blood gas
analysis were taken with the patients at rest.
When the individual patients were analysed,
at 2 h moderate respiratory depression
(PaCO2 7 – 8 kPa) was seen in 4 patients in
the i.t. Mo group. All these 4 patients in
the i.t. Mo group had needed supplemen-
tation with i.v. PCA morphine during the
first 2 hours already. Two cases of serious
respiratory depression (PaCO2 > 8 kPa) were
observed in the i.t. Mo group at 4 and 5 h.
One patient in the i.t. Mo group required
naloxone for respiratory depression.
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Tab
le 22:
A
d
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ts in
 stu
d
ies II – V
Day 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Study II
Diclofenac 12 8 2 0 6 2 2 1 3 1 1 0 7 3 1 1 1 1 0 0 0 0 13 0 – – – – – –
Placebo 14 10 2 1 6 4 2 1 2 3 0 1 6 5 0 1 2 2 0 0 0 0 9 0 – – – – – –
Study III
Inter 14 9 2 1 9 4 2 1 3 2 0 0 4 1 0 0 1 1 0 0 3 0 0 0 – – – – – –
Epid 14 13 1 6 5 2 0 0 2 7 0 0 6 3 1 1 4 4 0 0 5 0 0 0 – – – – – –
Para 13 12 2 2 3 1 0 1 4 3 0 0 1 2 0 0 1 1 0 0 6 0 0 0 – – – – – –
Study IV
Diclofenac 5 3 2 0 2 1 0 0 4 0 0 0 0 1 0 1 0 0 0 0 0 0 – – – – – – – –
Ketorolac 7 4 0 0 2 1 1 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 – – – – – – – –
Placebo 8 6 0 1 2 1 1 2 1 1 0 0 0 0 0 0 0 2 0 0 0 0 – – – – – – – –
Study V
Intathecal – – – – 2 1 – – 2 4 – – – – – – – – – – 4 0 6 1 0 0 0 4 10 0
PCA–Mo – – – – 1 0 – – 0 0 – – – – – – – – – – 0 0 2 0 0 1 0 0 7 0
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8.5 Chronic pain after
thoracotomy
8.5.1 Incidence of chronic
postthoracotomy pain
In study I the incidence of persistent
postthoracotomy pain was 44% (n = 134)
with a mean follow-up time of 30 months
(15 – 48 months). In this study there was no
statistically significant difference between the
patients who still had pain and those who
were free of pain with regard to patient char-
acteristics or the pain treatment received
during the two first postoperative days.
In study VI persistent postthoracotomy
pain interfered with normal daily life in more
than 50% of the patients (Figure 12). Sleep
disturbances were reported by 25% – 30%
of the patients. Among the major factors
aggravating the pain the patients reported
carrying heavy objects, changes in the
weather, walking around, lying on the op-
erated side, sitting, feeling depressed and
working with the hand of the operated side.
Most patients experienced chronic postop-
erative pain around the scar. The pain was
described as aching pain and/or tenderness
by half of the patients and as numbness by
one fourth of the patients.
Figure 12: Limitation in daily life in study VI
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8.5.2 Severity and duration of
chronic pain after thoracotomy
(Studies I and VI)
In study I, there was a statistically sig-
nificant correlation between the nurses’ re-
ports on pain and the amount of opioids
the patients received during the 1st and 2nd
postoperative day and the amount of non-
steroidal anti-inflammatory drugs (NSAIDs)
given during the 1st postoperative day.
In study VI the incidence of chronic pain
was similar in patients with malignant and
benign disease. Interestingly, the patients
who had persistent postoperative pain 6
months after surgery had consumed signifi-
cantly more analgesics during the immedi-
ate postoperative period compared with the
patients without persistent pain. However,
there was no significant difference in the
reported intensity of pain one week after
surgery between patients with or without
chronic pain at 6 months.
In study I, the pain experienced during
the first postoperative week was rated as
minor by 60% of the patients, as consider-
able by 35% and as excruciating by 5%.
The obtained pain relief was considered
good in 60%, satisfactory in 38% and poor
in 2% of the answers. Interestingly, the pa-
tients who had chronic postthoracotomy
pain at the time of the interview had expe-
rienced significantly more pain immediately
after surgery than the patients who had no
chronic pain. There was a significant corre-
lation between severity of pain experience
and poor efficacy of pain relief, i.e. patients
who had experienced more pain also rated
their pain relief as poorer. There was no sta-
tistically significant correlation between the
patients’ experience of the severity of pain
and the amount of either opioids or NSAIDs
administered. In order to improve postop-
erative pain relief the patients stated in the
interview that they would have wanted ad-
ditional analgesia as follows: analgesics
more frequently (19%) or in higher dosages
(4%), local anaesthetic blocks (3%) or
NSAIDs (2%).
Chronic postthoracotomy pain was
localised in the area surrounding the inci-
sion in 82% of the cases in study I and in
90% of the cases in study VI. The pain was
described as aching or tender in 30 – 45%,
combined with numbness in 25 – 40%.
More than one type of pain was reported
by 40% of the patients. The pain descrip-
tions suggest an 8% incidence of intercos-
tal neuralgia (numbness with tenderness or
burning pain). Treatment consisting mainly
of analgesics was received by 66% of the
patients in study I.
8.5.3 Predisposing factors
In study VI, more severe chronic pain 3
and 6 months after surgery was associated
with higher consumption of NSAIDs during
the first five postoperative days (p = 0.04
and 0.03, respectively). Patients with no pain
or mild pain (n = 46) 6 months after sur-
gery had taken on average 3.2 daily doses
of NSAIDs during the first 5 postoperative
days while patients with moderate, severe
or excruciating pain (n = 17) had taken 4.4
daily doses of NSAIDs (p = 0.03). Patients
who had no pain or mild pain (n = 46) 3
months after surgery had been given a mean
of 62.8 mg (range 7 – 117 mg) opioids ex-
pressed as equianalgesic doses of morphine
during the first two postoperative days and
patients having moderate, severe or excru-
ciating pain (n = 17) had received 78.9 mg
(range 34 – 170 mg) opioids (p = 0.06).
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9  DISCUSSION
9.1 Methodological aspects
9.1.1 Assessment of analgesia
In study II the PCA device was used as a
tool to assess analgesia. The morphine bo-
lus dose was always the same, i.e. 3 mg
followed by a tail dose of 2 mg given over
60 min, and the dose was not adjusted ac-
cording the patient’s weight. Prestudy pain
scores could only be obtained for two of
the patients in each group, as patients were
generally unable to co-operate when arriv-
ing in the recovery room due to residual
anaesthesic effects. In the immediate post-
operative period the conventional 10-cm
visual analogue scale is generally difficult to
use as the patient’s psychomotor skills have
not yet recovered after emergence from
general anesthesia. A 50-cm visual analogue
scale was therefore used to assess the post-
operative pain in place of the conventional
scale (Tigerstedt and Tammisto 1988). In
study V postoperative pain was measured
only by VAS at rest. In studies II – IV pain
was assessed at rest, when moving and
when coughing. This is important, as pain
intensities are significantly higher e.g. when
coughing compared with at rest.
In study III, the patients in the three
groups titrated themselves to comparable
levels of analgesia (Ferrante et al. 1988).
Thus, in this situation, the consumption of
PCA morphine can be considered a valid
measure of the efficacy of the various local
anaesthetic blocks. One hour after surgery
pain at rest was surprisingly high in all three
groups in study III. The time interval between
injection of bupivacaine and assessment of
the patients’ blocks in the PACU was ap-
proximately one hour, which should have
been sufficient for development of the skin
analgesia associated with the three tech-
niques (intercostal, epidural or paraverte-
bral). Using peroperative opioids might have
produced superior pain relief in the imme-
diate postoperative period but such an ap-
proach might have obscured the potential
differences in the analgesic efficacy of the
three different local anaesthetic blocks. A
recent study has suggested certain predic-
tive factors of early morphine requirements.
These include certain ethnic groups, emer-
gency surgery, major surgery, surgery ex-
ceeding 100 min, pain score on arrival in
PACU, and intraoperative opioid dose
(Dahmani et al. 2001).
9.1.2 Sample size and study
design
It could be argued that the numbers of
patients in studies III and IV were too small
to reveal any significant difference between
the groups in the main parameter i.e. con-
sumption of morphine. However, in study II
a significant difference between the groups,
which received an intrathoracic intercostal
nerve block with and without intravenous
infusion of diclofenac, was detected with
similarly sized patient groups using con-
sumption of PCA morphine as the main in-
dicator of analgesic efficacy. A power cal-
culation suggests that 114 patients in each
treatment group would have been required
in study III to detect a difference of 20% in
the consumption of morphine. Likewise, in
study IV, with an α-error of 0.05 and β-
error of 0.20 the power analysis indicated
that ten patients would have been required
per group to detect a 75 mg difference in
the consumption of morphine between
the diclofenac and the placebo groups
during a 48-hour period. A standard devia-
tion of 58.6 (placebo) and a mean differ-
ence between the groups of 93 mg in 48
hours was used in this calculation. More-
over, the sample size calculation was based
on study II that had a similar study design.
The difference between the placebo and
diclofenac treatments in study IV, however,
was 57 mg during the first 44 hours. The
small size of the patient groups in study V
was due to the rareness of myasthenia
gravis.
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9.1.3 Ethical aspects
The Institutional Ethics Committees ap-
proved all study protocols. Two of the con-
secutive studies (III and V) were not placebo-
controlled as ethical reasons prohibited
double-blinding and placebo-controlling in
these studies. I.v. morphine with PCA de-
vice was used as rescue medication in all
consecutive studies. The fact that ten pa-
tients in the control group required addi-
tional i.m. doses of morphine indicates that
excess caution may have been exercised in
study II when programming the PCA-device
(Ferrante et al. 1988, Sudarshan et al. 1995).
The lock out time of 30 min was probably
too long. A better choice may have been to
abandon the tail dose and use a shorter lock
out time and a 1-hour maximum dose limit
(Silvasti et al. 1998).
9.1.4 Model of stress
Diclofenac 75 mg i.m. and ketorolac 30
mg i.m. have demonstrated equal efficacy
in pain reduction and opioid requirement
both after laparoscopy (O’Hanlon et al. 1996)
and after maxillofacial surgery (Tarkkila et al.
1996). While a significant morphine sparing
effect after thoracoscopic surgery through
use of both diclofenac and ketorolac was
detected in study IV, no significant differ-
ence could be found between the two
NSAIDs in this regard. One explanation for
this might, of course, be that the type of
surgery, i.e., thoracoscopy, caused less pain
than had been predicted when the study
was started. Confidence intervals of 95%
for cumulative morphine consumption sug-
gest some difference between the
diclofenac and ketorolac groups, though a
statistically significant distinction could not
be detected due to the small numbers of
patients in each group.
9.1.5 Assessment of respiratory
function
One of the hypotheses studied was that
unilateral analgesia with a paravertebral or
intercostal block on the side of the surgical
incision and wound would provide similar
analgesia to an epidural block but with bet-
ter preserved respiratory function. The ad-
vantage of a unilateral block concerning
respiratory function could not be shown in
study III. However, the spirometry values
were slightly less reduced after paraverte-
bral blocks than in the other two groups.
The difference was not statistically signifi-
cant. This finding is in line with the similar
opioid consumption and comparable VAS
values at rest in all three groups in study III.
Due to significant variations in the defi-
nition of respiratory depression between
different studies it was not possible to com-
pare the frequency of this symptom in the
studies conducted and the reference stud-
ies used. In some studies respiratory depres-
sion is defined as need for naloxone while
in others it is defined as a decline in respira-
tory rate and increase in CO2. Nevertheless,
in study V the spirometry values after ster-
notomy can be interpreted as a dynamic
measurement in which postoperative pain
plays a major role.
9.1.6 Haematological variables
When evaluating the effects of NSAIDs
on thrombocyte function no significant con-
clusions can be drawn from the platelet
counts alone. The platelet counts are af-
fected by bleeding and volume replacement,
and should thus at least be adjusted by the
haematocrit. The quality of information on
any effects of the NSAIDs on platelet func-
tion can be improved by using the platelet
adhesion test which measures the propor-
tion of functional thrombocytes. As a quali-
tative measure of viscoelastic clot strength,
thromboelastography examines the entire
blood coagulation (Mallett and Cox 1992).
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Thus, this test can be used to assess the in-
teraction of the protein coagulation cascade,
fibrinogen, and the platelet surface as a unit.
9.2 Analgesic efficacy
9.2.1 Diclofenac and ketorolac
While not in the domain of this thesis,
it is worth mentioning that in orthopaedic
surgery both diclofenac (Lindgren and
Djupsjö 1985) and ketorolac have previously
been shown to be effective in pain allevia-
tion. Both diclofenac and ketorolac have also
been shown to be equally effective in re-
ducing pain and opioid requirements after
laparoscopy (O’Hanlon et al. 1996), after
maxillofacial surgery (Tarkkila et al. 1996),
and after major surgery i.e. orthopaedic,
abdominal, gynaecological, urological, car-
diac and thoracic surgery (Forrest et al.
2002). As is widely known, however, the
results have been more varied after abdomi-
nal surgery (Hodsman et al. 1987, Tigerstedt
et al. 1987). A previous study (Rhodes et al.
1992) has shown diclofenac 75 mg i.m.
twice daily to have a significant morphine
sparing effect after thoracotomies. Similarly,
ketorolac has been shown to be effective in
postthoracotomy pain treatment (Power et
al. 1994, Carretta et al. 1996, Singh et al.
1997).
In study II, the diclofenac group showed
a notably lower morphine consumption
compared with the placebo group during
both the first and the second 24-h study
periods. In the immediate postoperative
period up to 2 h, the VAS values were sig-
nificantly lower (P < 0.05) in the diclofenac
group, in which the patients were given a
bolus dose of the study drug over the first
15 minutes after arrival in the PACU.
There was notably lower average con-
sumption of morphine by the diclofenac
group in study II during the second postop-
erative day (only 14 mg or less than 25% of
the dose required by the control group). This
effect is quite plainly demonstrated by the
decrease in the steepness of the slope of
the morphine consumption curve after the
first 24 hours in the diclofenac group which
is not present in the placebo group. The al-
leviating effect of NSAIDs on inflammation
at the wound site on the second postop-
erative day (Mather 1992, Moote 1992) may
be one factor explaining the reduction in
experienced pain. Alternatively, or addition-
ally, this could be the result of acute toler-
ance to morphine at higher doses (McQuay
et al. 1981).
In patients undergoing major thoracic
surgery administration of lysine acetyl sali-
cylate 1.8 g 6-hourly has been shown to
provide postoperative pain relief similar to
that derived from infusion of morphine 10
mg every six hours (Jones et al. 1985). In
contrast to a study by Pavy et al (Pavy et al.
1990) in which administration of in-
domethacin suppositories (200 mg daily)
after thoracic surgery resulted in a 30%
decline in papaveretum consumption over
48 h, study II demonstrated a clinically sig-
nificant reduction of 67% in morphine con-
sumption. One explanation for the smaller
opioid sparing effect of indomethacin in the
study by Pavy and co-workers as compared
with the results of study II might be that
the control patients in their study did not
receive enough papaveretum. This hypoth-
esis is supported by the fact that the pa-
tients treated with indomethacin had not
only significantly less pain at all evaluation
times (Pavy et al. 1990), but also consider-
ably less pain after physiotherapy than the
patients in the control group. Admittedly,
other factors such as the different NSAIDs
used and the different administration tech-
niques may also have played a role. The sub-
stantial difference between the two study
outcomes does, however, imply that the
design of the control group and the admin-
istration procedures may have a significant
impact on the clarity of the study outcome
and should therefore be given just as much
attention as the test group design.
Surprisingly, although VATS is consid-
ered a less traumatic procedure compared
with conventional thoracotomy (Landreneau
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et al. 1993) patients appear to experience
moderate or even severe pain immediately
after the procedure. Supporting these find-
ings, Kirby and co-workers (Kirby et al.
1995), while observing significantly more
postoperative complications in the thorac-
otomy group compared with VATS, found
no difference in postoperative pain between
the groups.
In study IV all operations were minor
thoracic procedures, i.e. biopsies of the lung
or of the pleura, sympathectomies or extir-
pations of small benign tumours. In line with
the findings of Landreneau and Kirby, the
small difference in pain experience was also
made evident by the mean cumulative con-
sumption of morphine during the first post-
operative day in this study which was only
17% less in the VATS placebo group than
after thoracotomies in a similarly designed
study (study II). Correspondingly, in the VATS
diclofenac group consumption of morphine
was 30% less than after thoracotomies in
diclofenac group. The fact that the patients
in study II had received intercostal blocks
with 0.5% bupivacaine might explain the
small difference between studies IV and II.
These various findings would imply that,
putting aside the clearly important differ-
ence in the level of postoperative complica-
tions, if the patients’ comfort is a signifi-
cant consideration, pain treatment is equally
imperative in both VATS and thoracotomies
irrespective of the apparent degree of
trauma.
No statistically significant difference in
the morphine sparing effects of the two
NSAIDs was shown in study IV, probably due
to the small sample size. While the 95% con-
fidence intervals for cumulative morphine
consumption indicated a possible difference
between the diclofenac and ketorolac
groups, this could not be verified due to the
small numbers of patients in each group.
Despite the fact that no difference was de-
tected between the two NSAIDs in this re-
gard, both were shown to have a significant
morphine sparing effect after thoracoscopic
surgery when compared to placebo.
9.2.2 Regional anesthesia
Study III indicates that intercostal block-
ade produced superior early analgesia com-
pared with continuous epidural and paraver-
tebral blockade. This is supported by the fact
that the patients in the intercostal group
only experienced significantly less pain when
coughing at 2 and 4 h after the operation
compared with the epidural group.
While the overall efficacy of the three
regional anaesthetic methods examined in
study III was not particularly good, the prac-
tically equal effectiveness of the intercostal
block and the two continuous blocks was
unexpected even though one-third of the
patients in a recent study had problems with
the epidural technique (McLeod et al. 2001).
Satisfactory pain relief was achieved in two-
thirds of the patients but one patient in five
experienced poor pain relief. The fact that
the intercostal block was just as good as
the two continuous blocks may be explained
by the intercostal block causing a prolonged
though small reduction in pain perception.
Furthermore, the relative ineffectiveness of
the two continuous blocks in study III might
be attributable to the relatively moderate
dose of bupivacaine (Dollery 1999c). The
study design prescribed a 0.25% solution
of bupivacaine and deliberately avoided ex-
ceeding the recommended daily dose of
bupivacaine (400 mg) (Martindale 2002).
Hence, the infusion volume of bupivacaine
used in the study may have been insuffi-
cient.
The relative ineffectiveness of the two
continuous blocks in study III might also be
explained by the phenomenon of disaggre-
gation (Conacher 2001). Continuous epi-
dural and paravertebral blocks with local
anaesthetics do not prevent ipsilateral shoul-
der pain as a result of phrenic nerve medi-
ated nociception of diaphragmatic irritation.
Burgess and co-workers demonstrated
shoulder pain in 86% of patients undergo-
ing either lobectomy or pneumectomy de-
spite continuous epidural analgesia with
fentanyl alone or with a combination of fen-
66
tanyl and bupivacaine and concluded that
there was a close relationship between the
shoulder pain and the transection of a ma-
jor bronchus (Burgess et al. 1993). Unfor-
tunately, study III did specifically address
shoulder pain. Addition of a suprascapular
nerve block did not relieve ipsilateral shoul-
der pain after thoracotomy in patients re-
ceiving thoracic epidural analgesia with a
combination of bupivacaine and fentanyl
(Tan et al. 2002). Curiously though, inter-
scalenic brachial plexus blockade with li-
gnocaine or with bupivacaine (Ng and Chow
1997) as well as blockade of the phrenic
nerve with lignocaine (Scawn et al. 2001)
have been shown to be effective in treat-
ment of ipsilateral shoulder pain after thora-
cotomy in patients with continuous thoracic
epidural blockade for treatment of postop-
erative pain. Still, one should keep in mind
that interscalenic brachial plexus blockade
and phrenic nerve blockade carry a risk of
diaphragmatic paresis that can impair the
cough mechanism and result in atelectasis
in the presence of intercostal motor weak-
ness caused by thoracic epidural block.
Previous studies (Kaplan et al. 1975,
Faust and Nauss 1976, Toledo-Pereyra and
DeMeester 1979) have advocated the use of
intrathoracic intercostal nerve blocks as a re-
liable method for immediate postoperative
pain relief as they are easy to perform during
the operation. Sabanathan and co-workers
(Sabanathan et al. 1988, Sabanathan et al.
1990) have supported these recommenda-
tions by showing that continuous paraverte-
bral blockade with bupivacaine provided sig-
nificantly superior pain relief and pulmonary
function after thoracotomy compared with
placebo. Using the same method as
Sabanathan and co-workers to perform con-
tinuous paravertebral blockade, Richardson
and co-workers demonstrated the combina-
tion of continuous paravertebral block,
NSAID and systemic opioid to be the most
effective pain treatment method after thora-
cotomy (Richardson et al. 1994, Richardson
et al. 1999). Owing to the differences in
methodology the findings in study III are
difficult to compare with the results of
Sabanathan and co-workers and Richardson
and co-workers. In study III, pain was treated
with blocks using only local anaesthetic so-
lutions combined with i.v. PCA morphine
whereas Richardson and co-workers addi-
tionally used diclofenac 50 mg 8-hourly orally
or rectally (Richardson et al. 1999). Further-
more, in study III the dose of bupivacaine was
exactly the same in the paravertebral and epi-
dural groups whereas Richardson and co-
workers used double the amount of local
anaesthetic solution in the paravertebral
group compared with the epidural group.
Regrettably, the only study (Matthews and
Govenden 1989) with results resembling
those of study III with epidural and paraver-
tebral local anaesthetic blocks providing
equally good postoperative analgesia after
thoracotomy, made no mention of use of
supplementary analgesics.
9.2.3 Intrathecal morphine
When residual anaesthesia and inci-
sional pain are combined with the dimin-
ished pulmonary reserves patients with my-
asthenia gravis are particularly vulnerable
to respiratory complications during the post-
operative period (Drachman 1994). With the
aim of optimising the immediate recovery
phase, study V was designed to utilise i.t.
Mo for poststernotomy pain relief. This choice
was further influenced by the assumption
that i.t. opioid analgesia is considered pre-
dictable, technically easy and reliable (Jahr
and Bjerke 1991). Disadvantages of i.t. opioid
analgesia include e.g., nausea, itching, and
respiratory depression (Stoelting 1989). With
respect to the technical performance i.t. ad-
ministration may also be regarded as supe-
rior to the epidural route (Jahr and Bjerke
1991). The results of study V supported ear-
lier reports that the peak effect of i.t. Mo
occurs at 4 to 7 hours (Bailey et al. 1993).
Study V appears to be the first study
evaluating the efficacy and respiratory ef-
fects of i.t. Mo in myasthenia gravis patients
who were extubated immediately after sur-
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gery. PCA morphine consumption and VAS
scores were used to assess analgesia in study
V. In this study the analgesia was equally
effective with i.t. Mo and i.v. PCA Mo.
The findings of study V are in line with
the hypothesis that the mechanism of the
analgesic action of i.t. Mo is mainly spinal
(Cousins and Mather 1984, Carr and Cous-
ins 1998). As anticipated, lower plasma mor-
phine levels were seen in the i.t. Mo group
during the immediate postoperative period
up to the first four hours. Also, pain control
was equally good in both groups during this
time period with lower i.v. morphine con-
sumption in the PCA Mo group than in the
i.t. Mo group. In this study plasma concen-
trations of morphine were measured for ad-
ditional clinical information only.
Myasthenia gravis is known for the di-
versity of its clinical and pathological mani-
festations and its immunological character-
istics (Compston et al. 1980, Drachman
1994). Nilsson and co-workers (Nilsson et al.
1989, Nilsson and Müller 1990) have associ-
ated occurrence of the combination of HLA-
B8 and anti-AChR-ab with neuromuscular
sensitivity to halothane or isoflurane. The
elevated anti-AChR-ab titre has also been
related to increased vecuronium sensitivity
(Nilsson and Meretoja 1990).
Assessed by VAS, study V demonstrated
equally good pain relief in the i.t. Mo group
and in the i.v. PCA Mo group, although the
latter group had a lower total consumption
of i.v. Mo. The morphine consumption of
the i.v. PCA Mo group is in accordance with
a study comparing two different methods
for thymectomy, i.e. median sternotomy and
thoracoscopic thymectomy, in patients hav-
ing MG (Rückert et al. 2000). The signifi-
cantly lower respiratory rate in the i.t. Mo
group compared with the i.v. PCA Mo group
during the first six postoperative hours might
have been due to central respiratory depres-
sion or could be an indirect sign of better
pain relief in the i.t. Mo group. The occur-
rence of sporadic respiratory depression sug-
gests that the PCA dose of morphine (30
µg/kg) used in combination with i.t. Mo may
have been too high. The i.t. dose of mor-
phine (10 µg/kg) was relatively high com-
pared with the IASP guidelines (Ready and
Edwards 1992) and doses used for coronary
surgery (0.3 to 0.5 mg) (Heres et al. 1998).
Hence, the need for supplemental doses of
i.v. PCA Mo among the i.t. Mo patients dur-
ing the first postoperative hours could be a
sign of confusion due to residual anaesthe-
sia or an indirect sign of some form of dis-
comfort other than pain since the VAS val-
ues were low.
This conclusion is in agreement with
previous observations where the recom-
mended PCA dose was 50% smaller than
normally when used concomitantly with i.t.
morphine (Gwirtz 1992). The dose of i.v.
PCA Mo used in the study was considered
safe and justified because the patients were
monitored continuously for the first 24
hours.
9.3 Respiratory function
One objective in study II was to explore
whether reduced morphine consumption
was reflected in improved respiratory func-
tion as measured by levels of PaCO2 and
PaO2. Such a phenomenon had been ob-
served in two previous studies where either
i.m. ketorolac or i.m. diclofenac was given
for pain relief following abdominal surgery
in a comparable experimental setting using
PCA (Gillies et al. 1987, Hodsman et al.
1987). Indeed, when compared with pre-
operative values, the increase in arterial
PaCO2 was significantly smaller in the
diclofenac group in study II. One plausible
explanation for the difference in the increase
of PaCO2 could be the reduced consump-
tion of morphine in the diclofenac group.
Other possible factors explaining the dis-
crepancy in the increase of PaCO2 in study
II, such as decreased body temperature or
lower metabolic rate, should also be con-
sidered (Mortola and Frappell 2000). These
factors may also account for the observed
beneficial effects of diclofenac infusion on
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arterial oxygenation. Support for this con-
cept has been provided by earlier studies
indicating that prostaglandin inhibitors may
improve peripheral tissue perfusion after
coronary artery bypass surgery (Kuttila and
Niinikoski 1989).
Based on a previous study comparing
postoperative pain and pulmonary function
after laparoscopic and open cholecystec-
tomy it could be expected that the type of
operation conducted would have an impact
on postoperative respiratory function
(Hendolin et al. 2000). The lower postop-
erative FEV1 values after thoracoscopy and
thoracotomy in control patients in studies
III and IV support this hypothesis. The
method of anaesthesia and postoperative
pain treatment has also been shown to have
an impact on postoperative respiratory func-
tion (Hendolin et al. 1987). Regrettably, it
was not possible to compare the impact of
different types of anaesthesia as one-lung-
ventilation is used for many thoracic opera-
tions and thus general anaesthesia is fre-
quently necessary.
It has been suggested that the impact
of anaesthesia and surgery on postopera-
tive lung function is related to the diaphrag-
matic dysfunction that is thought to be sec-
ondary to surgical irritation, abdominal dis-
tension, and inadequate pain treatment
(Miller et al. 1994). In a study by Rückert
and co-workers the immediate postopera-
tive lung function declined to 65% after
thoracoscopic thymectomy and to 35% af-
ter transsternal median thymectomy
(Rückert et al. 2000). An earlier study by
Cooper et al (Cooper et al. 1978) reported
a decrease of up to 50% in vital capacity
and peak flow rate in poststernotomy pa-
tients with normal muscle strength when
parenteral morphine was given for postop-
erative pain relief. In a cumulative meta-
analysis study by Ballantyne and co-work-
ers epidural opioids decreased the incidence
of atelectasis compared with systemic opio-
ids, and epidural local anaesthetics increased
PaO2 and decreased the incidence of pul-
monary infections and pulmonary compli-
cations overall compared with systemic opio-
ids (Ballantyne et al. 1998). The findings of
study V are at odds with these earlier con-
clusions. In this study respiratory function
was significantly better restored with i.t. Mo
than i.v. PCA Mo. Four hours postopera-
tively, FVC% in the i.t. Mo group had re-
covered to 60% and FEV1% to 57% of the
respective baseline values compared with
FVC% 32% (p < 0.05) and FEV1% 37% in
the PCA Mo group.
9.4 Safety variables
9.4.1 Kidney function
Patients undergoing thoracic operations
are often on restricted i.v. fluids to prevent
postoperative pulmonary complications. Par-
ticularly under increased surgical stress this
postoperative fluid restriction can be mani-
fested as reduced urine output in patients
receiving NSAIDs for postoperative pain re-
lief (Ellenhorn et al. 1997, Lee et al. 1999).
The amount of i.v. fluids was also restricted
in study II as the majority of the patients
underwent either pneumonectomies or
lobectomies. This was manifested particu-
larly in significantly reduced urine output in
the diclofenac group even when compared
with the admittedly low urine output in the
control group. Subsequently, diuresis re-
turned to preoperative values during the
second postoperative day and no increases
were seen in the plasma creatinine values.
In study IV the i.v. crystalloid fluid volumes
were comparable with those generally rec-
ommended for surgical patients (Kaye and
Grogono 2000) and no differences were
found between the groups in urine output
or serum creatinine values during the first
two postoperative days. These findings are
in accordance with the results of Fredman
and co-workers who investigated the influ-
ence of i.v. diclofenac on renal blood flow
and glomerular filtration in normovolemic
elderly patients undergoing major ortho-
paedic surgery (Fredman et al. 1995). Treat-
ment with nonsteroidal anti-inflammatory
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drugs alone is not considered a significant
risk factor for postoperative renal failure
(Kim et al. 1999, Rexrode et al. 2001).
9.4.2 Haematological effects
In a previous study Bricker et al. showed
no increase in perioperative blood loss dur-
ing transurethral prostatectomy after oral
diclofenac given in a dose of 200 mg in 24
hours (Bricker et al. 1987). Another study
(Campbell et al. 1990) demonstrated that
75 mg of i.m. diclofenac increased capillary
bleeding time which, however, was unaf-
fected when the same dose was given i.v.
The present studies (II and IV) showed no
effects of diclofenac or ketorolac on
haemostasis as compared with the control
group. This concurs with previous findings
by Gibbs and Reinhart (Reinhart et al. 1993,
Gibbs and Sear 1995). It should be noted,
though, that the patients in the two present
studies discussed had not had deep venous
thrombosis prophylaxis which could poten-
tially increase the risk of haemostatic com-
plications of NSAIDs (Yett et al. 1978, Faunø
et al. 1993).
No difference was found between the
groups either in the platelet adhesion test
or in any of the thromboelastography pa-
rameters at two hours from the beginning
of the infusion in studies II and IV, and there
were no differences in these parameters
at 24 hours from the beginning of the in-
fusion in study IV. While Power and co-
workers reported that platelet aggrega-
tion was significantly decreased one hour
after an i.m. injection of 1.2 mg/kg of
diclofenac (Power et al. 1990), these results
are not directly comparable with the find-
ings of the present studies as in the study
by Power and co-workers all patients had
been given heparin preoperatively. This
difference in the results could also be ex-
plained in part by the use of different tests
and a lower diclofenac dose (0.4 mg/kg in
2 hours) in the present studies compared
with the study of Power and co-workers
(1.2 mg/kg i.m.).
9.4.3 Plasma drug concentrations
Previous studies have demonstrated
much higher bupivacaine concentrations
(mean 4.92 µg/ml, maximum 7.48 µg/ml)
during continuous infusion in paravertebral
blocks (Berrisford et al. 1993). Toxic effects,
such as convulsions, have been reported at
venous blood levels of approximately 2 – 4
µg/ml of bupivacaine (Covino 1998) and,
at even lower plasma concentrations of
bupivacaine, some evidence of central ner-
vous system toxicity has been reported
(Denson et al. 1984).
Interestingly, in study III, there was no-
ticeable variation between individual pa-
tients in arterial plasma concentrations of
bupivacaine. This was particularly evident in
the paravertebral group in which the
bupivacaine concentrations were elevated
in all patients as late as 48 h after the start
of the infusion. This unevenness in the
bupivacaine plasma concentrations could be
due to adsorption from and leakage out of
the surgically created compartment and
may, as such, be difficult to avoid and thus
require careful observation. In the paraver-
tebral and the epidural groups the highest
individual concentrations of bupivacaine –
5.1 µg/ml and 1.88 µg/ml, respectively –
were observed 48 h after the beginning of
bupivacaine infusion while in the intercos-
tal group a peak concentration of 1.46 µg/
ml was observed 10 min after injection.
Nevertheless, no signs of bupivacaine tox-
icity were detected in any of these patients
under close observation during the first 24
h postoperatively. This might be explained
by a placebo-controlled study on the inci-
dence of CNS symptoms and changes after
intravenous infusion of bupivacaine and
ropivacaine which showed a difference in
tolerance between the maximum total
plasma concentration and the unbound
concentration (Knudsen et al. 1997) due to
only unbound drug being available for dis-
tribution to the tissues.
In study IV, the patients received a con-
tinuous infusion of either diclofenac or
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ketorolac for a period of 48 h. As diclofenac
and ketorolac have different elimination
half-lives (diclofenac 1 – 2 h vs. ketorolac
5 h) (Willis et al. 1979, Brocks and Jamali
1992) the plasma concentrations were also
measured for 48 h in order to ensure that a
steady state concentration was reached.
During this time there was higher
interindividual variability in the plasma con-
centrations in the ketorolac than in the
diclofenac group. Plasma concentration–
time curves for both diclofenac and
ketorolac show clearly that all patients
treated with either diclofenac or ketorolac
had measurable concentrations of NSAID in
the blood circulation. No obvious explana-
tion for these variations was detected. Nev-
ertheless, as with other NSAIDs, clinical ef-
ficacy is probably not directly related to the
plasma concentrations of diclofenac or
ketorolac (Dollery 1999a, Dollery 1999b)
and it was, therefore, decided that this did
not require further consideration.
According to previous studies (Rowland
and Tozer 1995) a steady concentration state
may be considered to have been reached in
3.3 half-lives, translating to about 16.5 h
for ketorolac and 3.5 – 6.5 h for diclofenac.
In a single dose study with healthy volun-
teers the Cmax after an i.v. bolus dose of
10 mg ketorolac was 2.39 ± 1.30 µg/ml
(mean ± SD). In a study by Jung (Jung et al.
1988) the mean plasma concentration af-
ter a ketorolac i.v. bolus dose of 10 mg fell
from approximately 1 µg/ml to 0.1 µg/ml in
10 h. In another study the mean plasma con-
centration of diclofenac after an i.v. bolus
dose of 50 mg fell from approximately 8
µg/ml to 0.5 µg/ml in 1 h (Willis et al. 1979).
Hence, it was expected that due to the ad-
ministration of a bolus dose of 10 mg
ketorolac the time to reach the concentra-
tion plateau would be shorter than 16.5 h
in study IV and, accordingly, the concentra-
tions of ketorolac and diclofenac reached a
steady state at about the same levels as in
the studies of Jung et al (Jung et al. 1988)
and Willis et al (Willis et al. 1979), respec-
tively.
9.5 Adverse events
9.5.1 Regional analgesia (study III)
A noteworthy observation in study III
was that altogether 14 patients experienced
moderate to severe respiratory depression.
These complications could be explained by
the relatively high doses of opioids in these
patients. Indeed, it was noted that nine of
the 14 patients with respiratory depression
symptoms had taken 1.5 – 2 times the mean
average opioid consumption observed in the
study. According to previous research find-
ings possible predisposing factors for respi-
ratory depression include obesity and hy-
pertension (Chung and Crago 1982). Res-
piratory acidosis and hypoxia may be detri-
mental for patients who have cardiac prob-
lems due to an increase in hypoxic pulmo-
nary vasoconstriction that may lead to car-
diac failure (Lindgren et al. 1991). Further,
acidosis may also potentiate the cardio-
toxicity of bupivacaine (Covino 1998). The
incidence of complications after the epidu-
ral catheteri-sation was low and only two
patients had to be removed from the study
group because of unsuccessful catheteri-
sation. This conforms with the findings of
the study by Giebler and colleagues in which
the overall incidence of complications after
thoracic epidural catheterisation was 3.1%
(Giebler et al. 1997).
9.5.2 Intrathecal morphine
(study V)
In study V, sporadic episodes of respira-
tory depression, ranging from moderate to
severe, were observed more frequently in
the i.t. Mo group. Interestingly, Gray and
co-workers reported good postoperative an-
algesia after thoracotomy with the same i.t.
Mo dose (10 µg/kg) as used in study V. Gray
and co-workers administered the i.t. Mo
dose postoperatively and only one case of
respiratory depression was observed among
their group of 50 patients (Gray et al. 1986).
Neustein and Cohen also noted only one
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case of respiratory depression among their
16 patients who were given i.t. Mo (12 µg/
kg) at induction of anaesthesia for
postthoracotomy pain (Neustein and Cohen
1993). Unfortunately, in these two studies,
unlike in study V, no PCA was used and the
evaluation of pain was observer-rated.
There appear to be only three reports
dealing with post-sternotomy pain in MG
patients in the literature (Ferretti et al. 1987,
Jahr and Bjerke 1991, Kirsch et al. 1991),
even though the epidural technique has
been recommended as the method of
choice for pain relief after transsternal
thymectomy in MG patients (Drachman
1994). Of these three previous reports only
the study by Kirsch et al is a controlled study
(Kirsch et al. 1991). The findings demon-
strated improved postoperative ventilatory
function due to use of preoperative lumbar
epidural morphine in MG patients under-
going transsternal thymectomy. Two out of
9 patients in the epidural group and 3 out
of 10 in the placebo group needed mechani-
cal ventilation for up to 3 days after sur-
gery. Four out of 9 patients in the epidural
group and 6 out of 10 in the placebo group
could not be extubated immediately (Kirsch
et al. 1991). Taking into account the earlier
reports and the high frequency of postdural
puncture headache found in study V, epi-
dural morphine analgesia might be a better
choice for poststernotomy pain in MG pa-
tients, assuming that ventilatory function
can be restored to the same degree as with
i.t. Mo.
In study V, the incidence of postdural
puncture headache, the intensity of which
exceeded that of poststernotomy pain, was
unusually high (4/10) when compared with
previous reports (Gray et al. 1986, Neustein
and Cohen 1993, Horlocker 2000). After the
second patient had complained of signifi-
cant headache the size of the needle used
was reduced to 27G in order to prevent
postpuncture headache. Despite this adjust-
ment headaches were still observed. Based
on findings in previous studies young age
(mean age: 35 ± 3.4 year), female gender
and the needle configuration used may have
been possible predisposing factors for
postpuncture headache in study V (Gielen
1989, Lynch et al. 1992, Horlocker 2000).
9.6 Chronic pain after thoracic
surgery (studies I and VI)
The incidence of chronic pain after tho-
racic surgery has been analysed in a few
studies. The reported incidence of persistent
postthoracotomy pain syndrome (PTPS) is in
the range of 22 – 67% (Kanner et al. 1982,
Matsunaga et al. 1990, Dajczman et al.
1991, Landreneau et al. 1994, Bertrand et
al. 1996, Katz et al. 1996, Obata et al. 1999)
whereas in recent studies the incidence of
chronic post-sternotomy pain after cardiac
surgery and transsternal thymectomy has
been reported to be about 30% (Kalso et
al. 2001, Meyerson et al. 2001).
The incidence of PTPS is reported to be
30 – 65% after posterolateral thoracotomy
(Landreneau et al. 1994, Obata et al. 1999)
and 20 – 60% after VATS (Landreneau et
al. 1994, Bertrand et al. 1996). This con-
curs well with our results after anterolateral
thoracotomy with a PTPS incidence of 44%
in study I and 61% in study VI.
It can be speculated that more tissue
injury causes more pain after surgery
(Kavanagh et al. 1994a). Patients undergo-
ing posterolateral thoracotomy have been
found to have a higher degree of intercos-
tal nerve impairment compared with pa-
tients undergoing muscle-sparing thorac-
otomy (Benedetti et al. 1998), which indi-
cates that one of the most important differ-
ences between the two operative proce-
dures lies in the neuropathic component of
postoperative pain. The patients undergo-
ing non-serratus-sparing antero-axillary tho-
racotomy had better pulmonary function
during the first week after surgery and sig-
nificantly reduced chest pain up to six
months after surgery than patients under-
going posterolateral thoracotomy (Nomori
et al. 1997). The patients undergoing VATS
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for pulmonary resection had less pain and
subjective shoulder dysfunction compared
with patients having thoracotomy when
assessed less than one year after surgery
(Landreneau et al. 1994). In both groups the
pain medication requirements were similar.
Intercostal nerve damage after thoracotomy
is most likely a major factor in the develop-
ment of PTPS, although the exact mecha-
nism is not known (Rogers and Duffy 2000).
Interestingly, in a recent study conducted in
thymectomy and coronary artery bypass
grafting (CABG) patients the localisation of
chronic pain after sternotomy was depen-
dent on the type of operation (Kalso et al.
2001). After thymectomies chronic pain was
located mainly around the sternotomy scar
whereas after CABG pain was also located
in the arm, shoulder and/or leg. Various
hypotheses have been postulated to explain
the chronic pain after sternotomy, i.e. inter-
costal neuralgia or neuroma caused by the
inserted sternal wires for example (Meyerson
et al. 2001) but the mechanism of the pain
is not yet fully understood.
Higher consumption of analgesics af-
ter surgery could be an indication of more
severe pain rather than of inadequacy of
postoperative pain management (Tammisto
1978). In this respect PCA would be a more
reliable method than the more conventional
treatment that was used in studies I and VI.
However, high consumption of analgesics
or more acute pain could also signal a lower
pain threshold, which could also be reflected
in the reports of chronic pain. This differen-
tiation was examined in the study by Katz
and co-workers (Katz et al. 1996) and
Kavanagh and co-workers (Kavanagh et al.
1994b) but due to the small number of pa-
tients no conclusions could be drawn from
these studies.
It has been suggested that peri- or post-
operative use of NSAIDs can decrease the
incidence of chronic postthoracotomy pain
(Sabanathan 1995). However, in study VI the
patients who had persistent postoperative
pain 6 months after thoracotomy had con-
sumed more NSAIDs during the immediate
postoperative period than the patients with-
out persistent pain. Again, the higher con-
sumption of NSAIDs may indicate more pain
experienced by the patients. The role of
NSAIDs or any analgesic intervention should
be studied in a different set-up with
standardised comparison of the treatments.
In studies I and VI parenteral opioids,
intraoperative intercostal blocks and NSAIDs
were used mainly for treatment of pain dur-
ing the immediate postoperative phases.
Thoracic epidural analgesia for treatment of
postthoracotomy pain combined with ad-
equate oral pain medication during the first
postoperative week and with effective pain
management at home resulted in a lower
frequency of PTPS than in studies I and VI
(Tiippana et al. 2003). Presumably the best
method to avoid PTPS is multimodal anal-
gesia during the first postoperative days and
regular follow-up of the patients after dis-
charge from the hospital combined with the
possibility of contacting the hospital in case
of problems in pain management.
Chronic postthoracotomy pain is a com-
bination of many components (Ashburn and
Staats 1999). Probably the most severe form
of pain is caused by intercostal neuralgia,
the incidence of which is reported to be
between 1 and 3% (Conacher et al. 1986).
Severe pain was reported by 4 – 5% of the
patients in study VI and this incidence re-
mained for 12 months. This may represent
the severe treatment resistant pain that is
seen by pain specialists. Chronic long-term
pain may also be a sign of recurrence of
malignancy (Kanner et al. 1982). In fact, one
of the problems when analysing the patient
data in study VI was the high proportion of
25% of patients who were lost to follow-
up because of premature death before the
end of the study. Excessive spreading of the
ribs using thoracic retractor can result in
posterior rib fractures at the costovertebral
junction and in painful costochondral sepa-
rations anteriorly (Hazelrigg et al. 1991,
Landreneau et al. 1994). VATS approaches
can also be associated with significant local
trauma to the chest wall structures that can
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result in chronic pain (Landreneau et al.
1994).
Throughout the present studies, the
patients themselves expressed how impor-
tant they consider postoperative pain treat-
ment following thoracic surgery. In fact, this
is clearly demonstrated by the high response
rate of 82 – 89% in both studies I and VI.
There was a high incidence of persistent pain
which was reported by 45 – 60% of the
respondents in these two survey studies, and
one can speculate that patients may have
been prompted to respond in the expecta-
tion that they might receive some further
treatment for their pain. Indeed, some pa-
tients expressed a wish to be further exam-
ined and treated for the pain.
9.7 Future
An integral part of the design of any
analgesic regimen after thoracic surgery
should be to allow the patient to take deep
expansive breaths, cough effectively enough
to clear airways and shift accumulating se-
cretions, and to cooperate with physio-
therapy in so called “stir up” regimens.
Probably the most noteworthy develop-
ments in the treatment of postthoracotomy
pain will occur in the field of surgery with
the increasing use of less traumatic opera-
tive methods, i.e. thoracoscopy. Neverthe-
less, special attention should also be given
to adequate postoperative pain treatment
after thoracic operations. At the present
time and in the near future the method of
choice will probably be multimodal analge-
sia, i.e. combination of various analgesic
techniques such as regional analgesia, sys-
temic use of opioids, and other drugs such
as NSAIDs, α2-adrenergic agonists and
NMDA-antagonists (Chia et al. 1998,
Tschernko et al. 1998, Tan et al. 1999). A
well-tailored postoperative pain control regi-
men requires careful consideration of the
possible risks and benefits to the patient. If
effective but invasive methods such as epi-
dural or i.t. opioids and local anaesthetics
are not feasible, continuous infusion of an
NSAID, e.g. diclofenac or ketorolac, during
two postoperative days following thoracic
surgery appears to be a valuable alternative
as it significantly reduces morphine con-
sumption and improves analgesia. The role
of COX-2 in central sensitisation and the
effectiveness and safety of selective COX-2
inhibitors will most likely be intensively stud-
ied in the future (Katz 2002).
Chronic pain is equally common follow-
ing surgery for benign and malignant dis-
ease. It can be anticipated that more effec-
tive methods of acute pain management, e.g.
pre-emptive analgesia, epidural infusions of
analgesic drug combinations, will reduce the
incidence of chronic postthoracotomy pain
(Møiniche et al. 2002). As postoperative pain
after thoracic operations may last up to six
months and may even become chronic (Kalso
et al. 2001), patients should be advised to
contact their doctor if the pain does not de-
crease or if it gets worse after primary heal-
ing of the wound. It is important that post-
operative follow-ups are continued after the
patients have been discharged from hospi-
tal.
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10 CONCLUSIONS
1. Acute postthoracotomy pain is usually severe, may require high doses of opioids
and can last several days. Postthoracotomy pain is especially severe when the pa-
tient moves or coughs.
2. I.v. diclofenac and ketorolac improved analgesia and significantly reduced morphine
consumption after thoracotomy. They were safe with regard to both haemostasis
and renal function. However, NSAIDs should be used cautiously in patients who are
at high risk of developing renal problems during surgery. Special attention should
be paid to fluid balance and urine output. None of the three local anaesthetic
techniques, i.e. intercostal, epidural or paravertebral, provided good pain relief af-
ter thoracotomy. The required PCA-doses of morphine were high and respiratory
depression occurred in one-third of the patients.
3. In MG patients i.t. morphine provided effective poststernotomy pain relief and sig-
nificantly improved ventilatory function when compared with PCA morphine dur-
ing the first 24 hours. The high frequency of postpuncture headache was a serious
disadvantage. Careful postoperative monitoring is needed during the first 24 post-
operative hours because of the compromised muscle strength in MG patients and
the possibility of respiratory depression due to pain therapy.
4. Chronic postthoracotomy pain is a major problem. With an incidence of 50% it is
equally common following surgery for benign and malignant diseases. Chronic pain
after thoracotomy is associated with higher consumption of NSAIDs during the first
five postoperative days, i.e. patients, who experience more pain during the first
week after surgery are at higher risk of developing a postthoracotomy pain syn-
drome than other patients. More studies are needed on the epidemiology and treat-
ment of chronic postthoracotomy pain.
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